

## **CURRICULUM VITAE as of 25 January 2024**

**STEFANO PALLANTI, M.D. PhD**

H-index: 67 (as of January 2024)

### EDUCATION

December 1983

Medical Doctorate Degree (M.D.) and European Medical License, 6-year course, final dissertation thesis "Life events and Depression"  
**University of Florence, School of Medicine, Florence, Italy**

November 1987

Residency In Psychiatry, 4-year course, final dissertation thesis "Life Events and Schizophrenia"  
**University of Florence, School of Medicine, Florence, Italy**

November 1988

Residency in NeuroPsychopathology admitted to the second year.  
**University of Florence, School of Medicine, Florence, Italy**

June 1993

Ph.D in Applied Pathophysiology, 4-year course, final dissertation thesis "Contingent Negative Variation in Normal Elderly Population "  
**University of Florence, School of Medicine, Florence, Italy**

June 1993

Postgraduate Certificate "Assessment of Stressful Life Events in psychiatry ",  
**Bedford College, London, UK**

October 1993

Visiting scientist, **University of Cambridge, UK**

September 2000

Education on the Protection of Human Subjects in Research, **Icahn School of Medicine at Mount Sinai, New York, USA**

May 2013

Certificate of Deep TMS Operation, completed by **Brainsway Inc., Israel**

November 2013

LPS act 5150 Training Certificate, **University of Davis, CA, USA**

November 2013

Epic Onboarding and Documentation Training, **University of Davis, CA, USA**

April 2017

HIPAA Protecting Patient Privacy Certificate 2017, **Stanford University, CA, USA**

August 2017

Harassment Prevention Training Certificate, **Stanford University, CA, USA**

April 2018

HIPAA Protecting Patient Privacy Certificate 2018, **Stanford University, CA, USA**

- March 2018 Epic Onboarding and Documentation Training, **Stanford University, CA, USA**
- May 2018 Certificate of completion of Electroconvulsive Therapy Training, completed by **Villa Baruzziana, Ospedale privato accreditato Neuropsichiatrico, Bologna, Italy**
- July 2018 Biomedical Research 1 Certificate, **Albert Einstein College of Medicine, New York, USA**
- July 2018 Biomedical Research 2 Certificate, **University of California Davis, CA, USA**
- September 2018  
GCP for Clinical Trials with Investigational Drugs and Medical Devices – USA,  
FDA Certificate, **Albert Einstein School of Medicine**

## MEDICAL LICENSES

**Italian Licence to Practice, Registration at the Provincial Association of Doctor-Surgeons and Dentists in Florence, Italy:** Licenced on 30 November 1983, Registered on 23 January 1984, Licence number 7745

**General Medical Council (UK) Registration:** 18 June 2012, Registration n°7125393

**Schweizerische Eidgenossenschaft (Swiss Confederation) Registration:** 7 November 2012, Registration n° GNL7601000979667

**Medical Board of California, USA:** November 13, 2013 - November 13 2014, Registration n°F5799, NPI n° 19322939038, DEA Registration number: FP4286628 (2113 Permit)

**Medical Board of California, USA:** March 29, 2018 - December 12, 2019, Registration n°SFP000035, NPI n° 19322939038, DEA Registration number: FP4286628 (2168 Permit)

## PROFESSIONAL APPOINTMENTS

### Present Employment

Since 1989 Founder, Owner, CEO, Administrator, Strategic and Scientific Director, **Istituto di Neuroscienze, Via A. Lamarmora 24, Firenze, Italy**, A private institution for research, diagnosis, rTMS and tDCS therapy in Psychiatry, Neurology and Clinical Psychology. Accredited by the University of Florence for Post-Graduate Internship.

Since 2004 Founder, Director and Administrator, **Clinical Neurosciences ONLUS, Via Dè Fossi 12, Firenze, Italy**, A non-profit organization that organizes scientific CME courses in collaboration with the University of Florence (Italy)

### Academic Appointments

- Since 2000 Visiting Professor, **Icahn School of Medicine at Mount Sinai, New York, USA**
- 2001 – 2020 Tenured Professor of Psychiatry **University of Florence, School of Medicine, Florence, Italy**
- 2000 – 2010 Scientific Secretary and Coordinator, **Tuscany School of Psychiatry** (Three Tuscan Universities' Consortium: University of Florence, Pisa and Siena)
- 2004 – 2020 Board Member and Coordinator, **International Affairs Office of the University of Florence**
- Since 2004 Member of Board of Directors, International Master in Affective Neuroscience, **University of Maastricht, The Netherlands and University of Florence, Italy**
- 2004 – 2005 Visiting Associate Professor in Overseas Studies, **Stanford Program in Florence, School of Humanities and Sciences, Stanford University**
- 2004 – 2005 Professor in Emergency Psychiatry, Emergency Medicine Post Doctorate Master course, **Harvard School of Medicine, Massachusetts, U.S. and University of Florence, Florence, Italy**
- 2006 – 2007 Executive Director, Medical School Course of Psychiatry in English, **University of Florence, Italy**
- 2007 – 2008 Founder and Executive Strategic Director, Strategic Center of Excellence of Psychiatry, **Icahn School of Medicine at Mount Sinai New York, USA**
- 2008 – 2020 Member of Board of Directors, Dottorato Toscano di Neuroscienze, **University of Florence, School of Medicine, Florence, Italy**
- 2008 – 2010 Director of Master in Mindfulness (“Meditation and Mindfulness: Neurosciences and Clinical applications in Health Care”) **University of Florence**
- 2010 – 2020 President of the Graduate Course on Health Education, **University of Florence, School of Medicine, Florence, Italy**
- 2010 – 2020 President of Education and Director of the Residency Program in Psychiatry, **University of Florence, School of Medicine, Florence, Italy**
- Since 2012 Italian National Scientific Qualification as a full professor
- 2013 – 2014 Professor of Psychiatry and Behavioral Sciences, Early Diagnosis and Preventive Treatment Clinic, Psychosomatic Unit, Responsible for the Neuromodulation Program, **UC Davis, CA, USA**
- Since 2013 Adjunct Associate Professor, **Albert Einstein College of Medicine, Montefiore Medical Center New York, USA**
- Since 2016 Visiting Professor, **Imperial College, London, UK**

- 2017 – 2019 Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology (Adult), TMS Consultant, Head of ADHD Clinic, **Stanford University, Stanford, CA, USA**
- Since 2018 Faculty, **Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale**
- Since 2019 Faculty, The European Network for Problematic Usage of the Internet, **Training School at Clare College, Cambridge University**
- Since 2019 Faculty, International Psychopharmacology Course, **Harvard University and Massachusetts General Hospital Psychiatry Academy**
- Since 2022 Honorary Professor, Instituto Universitario de Neurociencias, **Universidad de La Laguna, San Cristóbal de La Laguna, Spagna**

### Clinical Activities

- 1984 –1988 Chief Residency in Psychiatry
- 1988 –1990 Residency in Neurology
- 1990 –1993 Residency in Clinical Neurophysiology
- Since 1989 Private practice as a Clinical Director, **Istituto di Neuroscienze, Italy**
- 2000 – 2020 Dirigente Medico 1<sup>st</sup> level (Medical Director), **Psychiatric Clinic, Department of Neuropharba, Azienda Ospedaliero Universitaria Careggi (University of Florence Hospital),**
- 2000 – 2020 Director of the OCD Spectrum Disorders programme, Psychiatric Clinic, **Department of Neuropharba, Azienda Ospedaliero Universitaria Careggi, University of Florence Hospital**
- 2001 Director, Adult ADHD Program, **Department of Neuropharba, Azienda Ospedaliera Universitaria Careggi, University of Florence**
- 2001 Director, PANDAS - PANS Program, **Department of Neuropharba, Azienda Ospedaliera Universitaria Careggi, University of Florence**
- 2009 - 2014 Director of Psychosomatic and Liaison psychiatry, **Department of Neuropharba, Azienda Ospedaliera Universitaria Careggi, University of Florence**
- 2013 - 2014 Clinical Practice, Sacramento EDAPT and EDAP programs (Early Diagnosis and Preventing Treatment of Psychosis Illness), Liaison Psychiatry Consultant, **UC Davis Medical Hospital, CA, USA**
- 2018 - 2019 Professor of Psychiatry and Behavioural Sciences, **Stanford University, CA, USA**

## Professional Memberships and Services

- Since 1994 International Advisory Board member, ***American Psychiatric Association (APA) for DSM V and DSM 5.0 TR***
- Since 1999 Member of the Steering Committee, ***International OCD Consortium***
- Since 2000 Member of Board of Directors, ***International Master in Affective Neuroscience***, Universities of Maastricht and Florence
- Since 2004 Board member, ***International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), UK***
- Since 2004 Scientific Advisory Panel Member for Anxiety and Anxiolytics session, ***European College of Neuropsychopharmacology (ECNP)***
- Since 2005 Member of International Advisory Board, ***American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer)***
- 2005 - 2007 Member of the OCD spectrum workgroup Impulse Control Disorders Taskforce and International Advisory Board, ***American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer)***
- Since 2009 Member of the Advisory Council, ***icare4autism (International Center for Autism Research and Education), New York, USA***
- 2011 –2014 Member of the ***European College of Neuropsychopharmacology Educational Committee***
- Since 2011 Member of ***the ECNP Obsessive Compulsive and Related Disorders Network***
- Since 2013 Fellow, ***European College of Neuropsychopharmacology***
- Since 2013 Member of the ***New York Psychiatric Society, NY, USA***
- 2013 – 2017 Member of the Board of Directors, ***Clinical TMS Society, Greenwich, CT, USA***
- Since 2014 ***World Health Organization expert in Anxiety***
- Since 2014 International Fellow, ***American Psychiatric Association (APA)***
- Since 2015 Member of the Board, (anxiety section) ***World Psychiatric Association***
- 2016 - 2019 Executive Committee Member, ***European College of Neuropsychopharmacology***
- Since 2017 Ambassador, ***European College of Neuropsychopharmacology (ECNP)***
- Since 2017 Member of the ***PANDAS Physicians Network***

- Since 2018 Board member, **European Research Area Networks NEURON** (ERA-NET NEURON)
- Since 2019 Chair, Neuromodulation Network, **European College of Neuropsychopharmacology (ECNP)**
- Since 2020 International Expert, **German Association of Scientific Medical Associations on behalf of the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJPP)** for development of the interdisciplinary evidence- and consensus-based S3-Guideline for the diagnosis and treatment of obsessive-compulsive disorder in childhood and adolescence (interdisziplinäre evidenz- und konsensbasierte S3-Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter)
- Since 2020 Member of the **International Neuroethics Society**
- Since 2020 Board member, **The European Commission consensus initiative on depression and its treatment (EU PEARL)**
- Since 2021 Member, WHO - World Health Organization funded **COVID-19 Clinical Research Coalition's Ethics Working Group, the Good Clinical Practice Alliance – Europe (GCPA)**
- Since 2023 Member of the **World Health Network**

Service as a member of Grant Review Committee

- 2011 Member of Research Funding Evaluation Committee, **UK General Medical Research Council**
- Since 2011 Member of the Board of Research Funding Evaluation Committee SAMENTA, **Agence Nationale de la Recherche, Paris, France**
- 2013 Member of the Expert Review Board, The **ERA-NET scheme of the European Commission 'Network of European Funding for Neuroscience Research' (NEURON)** for its funding initiative "European Research Projects on Mental Disorders"
- Since 2018 Member of the Spark Evaluation Committee, **the Swiss National Science Foundation (SNSF)**
- 2020 Specialist Evaluating Committee Member, **the National Research Foundation (NRF), South Africa**
- 2020 Board of Reviewers, Catalan biomedical research funding programme "La Marató de TV3", **Agency for Health Quality and Assessment of Catalonia, Spain**
- 2023 Specialist Evaluating Committee Member, **the National Research Foundation (NRF), South Africa**

- 2024 Committee Peer Reviewer, **International OCD Foundation Grant Program (IOCDF), USA**
- 2024 Grant Review Committee Member, **The Netherlands Organisation of Health, Research and Development (ZonMw)**

### Professional Honors and Awards

- October 2004 ECNP poster-travel award
- February 2005 Società Italiana di Psicopatologia (SOPSI) poster research award
- May 2007 CNS Spectrum 2007 Breakthrough Paper Award

### TEACHING

#### University of Florence, Italy

- 1993 - 2019 Psychopathology Course (Course Director and Lecturer)
- 1993 - 2019 Psychopathology in the Residency Programme (Course Director and Lecturer)
- 2000 - 2019 Undergraduate Psychiatry Course (Course Director and Lecturer)
- 2001 - 2019 Medical Thesis Advisor
- 2006 - 2007 English language Medical School Course of Psychiatry (Director)
- 2007 - 2019 Suicide Prevention Course for Medical students, Nurse and Social Workers (Director)
- 2010 – 2020 Chair of Education
- 2010 - 2019 Psychopharmacology Course (Course Director and Lecturer)
- 2010 - 2020 Residency program (Course Director and Lecturer)
- 2010 - 2020 Post-Graduate Psychiatry Course (Course Director and Lecturer)
- 2011 - 2018 Undergraduate course in Psychiatry (Course Director and Lecturer)
- 2012 - 2012 Master's Program in Mindfulness (Director)
- 2016 - 2017 Neurocircuitry Research Domain Criteria and Precision Psychiatry Course (Course Director and Lecturer)

#### Weekend Educative Course in Psychiatry, India

- 2017 – 2018 Elite faculty for enforcement program of neuropsychiatry in India

University of Maastricht and University of Florence,

1995 - Present International Master Degree in Affective Neuroscience (joint program) - course design, material development, lectures, and thesis advising

Continuing Medical Education (CME) European Accreditation Council for CME

2009 - 2013 Managing Anxiety in Practice CME Course design, course material development (Slides, Booklet and CD-ROM) and lectures. Total of 6 courses held in Berlin (Germany), London (UK), Athens (Greece), Rome (Italy), Munich (Germany) and Paris (France)

Florence Summer Course – Organizer, Scientific Director, Chair and Speaker

2004	7 - 14 Aug.	Anxiety and Impulsivity
2005	30 July - 1 Aug.	Neuroscience of Affective Disorder Spectrum
2006	14 -15 Sept.	Psychiatric Disorder and Day Hospital
2007	31 Ago. - 3 Sept.	Anxiety Disorders and Psychosis
2008	4 - 6 Sept.	Aspect of Contemporary Psychiatric Disorders
2009	5 - 7 Sept.	A Lesson on Great American Studies on Efficiency and Personalized Therapies in Psychiatry
2010	3 - 5 Sept.	Aspect of Contemporary Psychiatry
2011	9 - 11 Sept.	Toward and Individualized Therapy – Evolution of Psychiatry, from Disorder to “Research Domain”
2012	19 - 21 Oct.	Quality in Clinical Psychiatry
2013	11 - 12 Oct.	Clinical Staging and Pathophysiology of Brain Disease
2014	23 - 24 Oct.	Total Resources: Look after Brain Disorders and Take Care of Mental Suffering

European College of Neuropsychopharmacology (ECNP)

Since 2020 Founder, organizer and speaker, Master Training Class in Neuromodulation, Neuromodulation Network

Since 2020 Organizer and speaker for ECNP Network, Thematic Working Group

Training Courses for Health Care Providers

2019 TMS Course for Ospedale Privato Villa Baruzziana, Bologna

2022 TMS Course for Istituti Clinici Zucchi, Monza



2022 TMS Course for ASL Napoli 2 Nord (Azienda Sanitaria Locale, Public Health Care Company), Napoli

Coordinator, Interuniversity cooperation agreements

2004 - 2020 Board member of the International Affairs Office of the University of Florence, International educational collaborative programmes between University of Florence and:

Columbia University (USA) in 2010  
University of Balamand (Lebanon) in 2009  
Mount Sinai School of Medicine (USA) in 2004  
Stanford University (USA) in 2004

SCHOLARSHIP

Peer-Reviewed Original Research Publications (extracts)

1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, **Pallanti S**, Vita A. Recent life events and affective disorder revisited. *British Journal of Psychiatry*. 1986 Mar;148:288-95.
2. Faravelli C, Ambonetti A, **Pallanti S**, Pazzagli A. Depressive relapses and incomplete recovery from index episode. *American Journal of Psychiatry*. 1986 Jul;143(7):888-91.
3. Faravelli C, **Pallanti S**. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. *Psychopharmacol Bull*. 1987;23(3):459-63.
4. Faravelli C, **Pallanti S**, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic attacks with and without agoraphobia: a comparison. *Psychopathology*. 1988;21(1):51-6.
5. Faravelli C, **Pallanti S**, Strik WK. [Stress load and schizophrenic disorder]. *Nervenarzt*. 1988 Apr;59(4):237-9. German.
6. Faravelli C, **Pallanti S**. Recent life events and panic disorder. *American Journal of Psychiatry*. 1989 May;146(5):622-6.
7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G, Faravelli C, **Pallanti S**, Bressa G. Familial analysis of panic disorder and agoraphobia. *Journal of Affective Disorders*, 1989, vol.17, p.1-8. ISSN: 0165-0327.
8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, **Pallanti S**. Epidemiology of mood disorders: a community survey in Florence. *Journal of Affective Disorders*. 1990 Oct;20(2):135-41.
9. Faravelli C, Panichi C, **Pallanti S**, Paterniti S, Grecu LM, Rivelli S. Perception of early parenting in panic and agoraphobia. *Acta Psychiatrica Scandinavica*. 1991 Jul;84(1):6-8.

10. Faravelli C, **Pallanti S**, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder. *American Journal of Psychiatry*. 1992 Jun;149(6):827-8.
11. **Pallanti S**, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. *Biological Psychiatry*. 1992 Jul 1;32(1):91-5.
12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, **Pallanti S**, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease. *Journal of the Neurological Science*. 1992 Oct;112(1-2):81-9. Volume 112, Issues 1–2, 1992,  
Pages 81-89. ISSN 0022-510X. [https://doi.org/10.1016/0022-510X\(92\)90136-9](https://doi.org/10.1016/0022-510X(92)90136-9).
13. a. (<https://www.sciencedirect.com/science/article/pii/0022510X92901369>)
14. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli, **S.Pallanti**, J.Lepine, P.Pariante, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori, W.Maier (1992). The changing rate of depression. *JAMA*, vol. 268, p. 3098-3105, ISSN: 0098-7484.
15. **Pallanti S.**, Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica. [Dementia in a psycho(patho)logical perspective] *Jornal Brasileiro de Psiquiatria [Brazilian Journal of Psychiatry]* 41 (9), 447-50. Ott. 1992.
16. Faravelli C., **Pallanti S.**, Biondi F., Paterniti S., Scarpato M.A. Assessment of onset of panic disorder in relation to onset of agoraphobia-replay. *American Journal of Psychiatry* 150 (9), 1437-1437. 1993-09-01.
17. **Pallanti, S.** et al. Depth perception in schizophrenia. *Biological Psychiatry*, Volume 35, Issue 9, 637 – 638 Published in issue: May 01, 1994
18. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, **Pallanti S**, Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and Russian families with schizophrenia. *Neuroscience Letters* 1994 Jan 3;165(1-2):45-7.
19. Grassi E, Mortilla M, Amaducci L, **Pallanti S**, Pazzagli A, Galassi F, Guarnieri BM, Petrucci C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in Italian pedigrees. *Neuroscience Letters* 1996 Mar 15;206(2-3):196-8.
20. **Pallanti S**, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-compulsive disorder. *Biological Psychiatry*. 1996 Dec 1;40(11):1164-72.
21. **Pallanti S**, Koran LM. Two case report. *CNS Spectrums* 1996, vol.1, p.54-57, ISSN: 1092-8529.
22. Bersani G., Saito A. **Pallanti S**. Sasso E., Tosca P. Clinical variables and response to citalopram in Major Depression: an open multicentric study. *Rivista di Psichiatria* 32, 260-267, 1997.

23. **Pallanti S.** Personality Disorders: Myths and Neuroscience. *CNS Spectrums* 2, 53-63, 1997.
24. Koran LM, Sallee FR, **Pallanti S.** Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. *American Journal of Psychiatry.* 1997 Mar;154(3):396-401.
25. **Pallanti S,** Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. *American Journal of Psychiatry.* 1997 Jun;154(6):792-8.
26. Ramacciotti A, **Pallanti S,** Pazzagli A. A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity. *Eating and Weight Disorders.* 1997 Dec;2(4):222-8.
27. Inzitari D, Pantoni L, Lamassa M, **Pallanti S,** Pracucci G, Marini P. Emotional arousal and phobia in transient global amnesia. *Archives of Neurology.* 1997 Jul;54(7):866-73.
28. **Pallanti S,** Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. *Eating and Weight Disorders.* 1997 Dec;2(4):216-21.
29. **Pallanti S,** Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. *Psychiatry Research.* 1998 Mar 20;78(1-2):59-70.
30. Koran LM, **Pallanti S,** Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. *Eur Neuropsychopharmacol.* 1998 May;8(2):121-6.
31. Sallee FR, Koran LM, **Pallanti S,** Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. *Biological Psychiatry.* 1998 Aug 1;44(3):220-7.
32. **Pallanti, S.,** Quercioli, L. Cognitive subjective disturbances of schizophrenia: Effect of atypical neuroleptics. *European Neuropsychopharmacology,* 1999
33. **Pallanti S.,** Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 203-203, 1999-01-01.
34. **Pallanti S,** Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. *American Journal of Psychiatry.* 1999 May;156(5):796-10327919.
35. **Pallanti S,** Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. *Psychiatry Research.* 1999 Jun 30;86(3):239-49.
36. **Pallanti S,** Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. *American Journal of Psychiatry.* 1999 Jul;156(7):1094-6.

37. **Pallanti S**, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. *European Psychiatry*. 1999 Apr;14(2):101-6.
38. **Pallanti S**, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. *Comprehensive Psychiatry*. 1999 Sep-Oct;40(5):363-71.
39. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, **Pallanti S**, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. *British Journal of Psychiatry* 1999.467-71.
40. **Pallanti S**, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. *Journal of Clinical Psychiatry*. 1999 Dec;60(12):819-23.
41. Di Russo F, Zaccara G, Ragazzoni A, **Pallanti S**. Abnormal visual event-related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. *Journal of Psychiatric Research*. 2000 Jan-Feb;34(1):75-82.
42. **Pallanti S**, Quercioli L. Shame and psychopathology. *CNS Spectrums*. 2000 Aug;5(8):28-43.
43. **Pallanti S**, Quercioli L, Pazzagli A. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. *CNS Spectrums*. 2000 Sep;5(9):29-43.
44. Rossi A, Arduini L, Stratta P, **Pallanti S**. Subjective experience and subjective response to neuroleptics in schizophrenia. *Comprehensive Psychiatry*. 2000 Nov-Dec;41(6):446-9.
45. Koran LM, **Pallanti S**, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. *European Neuropsychopharmacology*. 2001 Apr;11(2):169-72.
46. Hollander E., Bienstock C.A., Koran L.M., **Pallanti S.**, Marazzini D., Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. *Journal of Clinical Psychiatry* 63, 20-29, 12-2001.
47. **Pallanti S.**, Quercioli L. Alternative route of administration and titration of SRIs in anxious resistant patients:Two day-hospital experiences. *European Neuropsychopharmacology* 11, S312, 2001-12-31.
48. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, **Pallanti S**. Attachment processes in eating disorders. *Eat Weight Disord*. 2001 Sep;6(3):166-70.
49. Presta S, Marazziti D, Dell'Osso L, Pfanner C, **Pallanti S**, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. *Comprehensive Psychiatry*. 2002 Jan-Feb;43(1):7-12.
50. Hollander E, Bienstock CA, Koran LM, **Pallanti S**, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory

- obsessive-compulsive disorder: state-of-the-art treatment. *Journal of Clinical Psychiatry*. 2002;63 Suppl 6:20-9.
51. **Pallanti S**, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. *International Journal of Neuropsychopharmacology*. 2002 Jun;5(2):181-91.
  52. **Pallanti S**, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. *Journal of Clinical Psychiatry*. 2002 Jul;63(7):559-64.
  53. **Pallanti S**, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. *Journal of Clinical Psychiatry*. 2002 Sep;63(9):796-801.
  54. **Pallanti S**, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. *Journal of Clinical Psychiatry*. 2002 Nov;63(11):1034-9.
  55. Buchsbaum M.S., Hollander E., **Pallanti S**., Baldini-Rossi N. Brikman A.M., Platholi J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in SRI-refractory patients. *Biological Psychiatry* 51 (8), 47S-47S, 2002-04-14.
  56. **Pallanti S**., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse-Control Disorders Not Otherwise Specified (NOS). *Biological Psychiatry* 2003, 1315-1329.
  57. Sood ED, **Pallanti S**, Hollander E. Diagnosis and treatment of pathologic gambling. *Current Psychiatry Reports*. 2003 May;5(1):9-15.
  58. Hollander E, Baldini Rossi N, Sood E, **Pallanti S**. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. *International Journal of Neuropsychopharmacology*. 2003 Dec;6(4):397-401.
  59. **Pallanti S**, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. *American Journal of Psychiatry*. 2004 Jan;161(1):53-8.
  60. **Pallanti S**, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. *Journal of Clinical Psychiatry*. 2004 Oct;65(10):1394-9.
  61. **Pallanti S**, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. *Journal of Clinical Psychiatry*. 2004;65 Suppl 14:6-10.
  62. Hollander E, **Pallanti S**, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? *American Journal of Psychiatry*. 2005 Jan;162(1):137-45.

63. Hollander E, Sood E, **Pallanti S**, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. *Journal of Gambling Studies*. 2005 Spring;21(1):99-110. 21, 99–108 (2005). <https://doi.org/10.1007/s10899-004-1932-8>
64. Haznedar MM, Roversi F, **Pallanti S**, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. *Biological Psychiatry*. 2005 Apr 1;57(7):733-42.
65. Urpe M, **Pallanti S**, Lotti T. Psychosomatic factors in dermatology. *Dermatologic Clinics*. 2005 Oct;23(4):601-8.
66. **Pallanti S**, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: from empiric data to the evolutionary hypothesis. *Dermatologic Clinics*. 2005 Oct;23(4):695-701.
67. Hollander E, **Pallanti S**, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS. Imaging monetary reward in pathological gamblers. *World Journal of Biological Psychiatry*. 2005;6(2):113-20.
68. **Pallanti S**, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. *Clinical Practice & Epidemiology in Mental Health*. 2005 Nov 15; 1:24.
69. **Pallanti S**, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability, and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). *Journal of Gambling Studies*. 2005 Winter;21(4):431-43.
70. **Pallanti S**, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria C. M., & Hollander E. (2010). Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. *Journal of Psychopharmacology (Oxford, England)*, 24(6), 847–853.
71. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, **Pallanti S**, Endicott J; (For the EQUIP group). Reliability and validity of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. *Quality of Life Research*. 2005 Dec;14(10):2323-8.
72. **Pallanti S**, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2006 May;30(3):400-12.
73. **Pallanti S**. (2006). From Impulse-Control Disorders Toward Behavioral Addictions. *CNS Spectrums*. 11. 921-922. [10.1017/S1092852900015108](https://doi.org/10.1017/S1092852900015108).
74. Buchsbaum MS, Hollander E, **Pallanti S**, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. *Neuropsychobiology*. 2006;53(3):157-68.

75. **Pallanti S**, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. *CNS Spectrums*. 2006 Dec;11(12):956-64.
76. **Pallanti S**, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high-school population: prevalence and related disability. *CNS Spectrums*. 2006;11(12):966-74.
77. **Pallanti S**, Quercioli L. Resistant social anxiety disorder response to Escitalopram. *Clinical Practice & Epidemiology in Mental Health*. 2006;13; 2:35.
78. Hollander E, Kim S, Khanna S, **Pallanti S**. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. *CNS Spectrums*. 2007 Feb;12(2 Suppl 3):5-13.
79. Fineberg NA, Pampaloni I, **Pallanti S**, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. *International Clinical Psychopharmacology* 2007;22(6):313-22.
80. **Pallanti S**, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. *International Journal of Psychiatry in Clinical Practice*. 2007; 11(3): 233-238.
81. **Pallanti S**. Transcultural observations of obsessive-compulsive disorder. *American Journal of Psychiatry*. 2008 Feb;165(2):169-70.
82. **Pallanti S**, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive compulsive disorder comorbidity in DBA. *Clinical Practice & Epidemiology in Mental Health*. 2008 Mar 10; 4:6.
83. La Malfa G, Lassi S, Bertelli M, **Pallanti S**, Albertini G. Detecting attention-deficit/hyperactivity disorder (ADHD) in adults with intellectual disability the use of Conners' Adult ADHD Rating Scales (CAARS). *Research in Developmental Disabilities*. 2008 Mar-Apr;29(2):158-64.
84. **Pallanti S**. Brain plasticity and brain stimulation in neuropsychiatry: toward individualized medicine. *CNS Spectrums*. 2008 Apr;13(4):287-92.
85. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, **Pallanti S**. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral, and cingulate metabolism. *Neuropsychobiology*. 2008;58(1):37-47.
86. **Pallanti S**, Hollander E. Obsessive-compulsive disorder spectrum as a scientific "metaphor". *CNS Spectrums*. 2008 Sep;13(9 Suppl 14):6-15.
87. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., **Pallanti S.**, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder. *Biological Psychiatry* 63 (7), 170S-170S, 2008-04-01.

88. **Pallanti S**, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. *International Clinical Psychopharmacology* 2009 Jul;24(4):163-73.
89. Faravelli C, Lo Sauro C, Castellini G, Ricca V, **Pallanti S**. Prevalence, and correlates of mental disorders in a school-survey sample. *Clinical Practice & Epidemiology in Mental Health* 2009 Nov 24; 5:1-8.
90. **Pallanti S**, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA. Cognitive event-related potentials differentiate schizophrenia with obsessive-compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. *Psychiatry Research*. 2009 Nov 30;170(1):52-60.
91. Potenza MN, Koran LM, **Pallanti S**. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. *Psychiatry Research*. 2009 Nov 30;170(1):22-31.
92. Bernardi S, **Pallanti S**. Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. *Comprehensive Psychiatry*. 2009 Nov-Dec;50(6):510-6.
93. **Pallanti S**, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. *CNS Drugs*. 2009 Dec;23(12):1047-55.
94. Lisanby SH, **Pallanti S**, Schlaepfer TE. FDA considers classification of ECT. *CNS Spectrums*. 2009 Dec;14(12):668-70.
95. **Pallanti S**, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? *Neuroscience*. 2010;5;167(2):323-8.
96. **Pallanti S**, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S. Complex repetitive behavior: punning after bilateral subthalamic nucleus stimulation in Parkinson's disease. *Parkinsonism and Related Disorder*. 2010 Jul;16(6):376-80.
97. Cecchelli C, Grassi G, **Pallanti S**. Aripiprazole Improves Depressive Symptoms, and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. *Case Reports in Medicine*. 2010; 2010:836214.
98. Schlaepfer TE, Lisanby SH, **Pallanti S**. Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. *CNS Spectrums*. 2010 May;15(5):285-7.
99. **Pallanti S.**, Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive Transcranial Magnetic Stimulation and Depression: Separating Hope From Hype. *CNS Spectrums* 15 (9), 554-557, 2010.
100. **Pallanti S**, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS. Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. *Neuropsychobiology*. 2010;62(2):132-8.



101. **Pallanti S.** Problematic Internet use: is it more compulsory than rewarding or mood driven? *World Psychiatry.* 2010 Jun;9(2):96-7.
102. Bernardi S, Cortese S, Solanto M, Hollander E, **Pallanti S.** Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? *Clinical characteristics and temperamental traits. World Journal of Biological Psychiatry.* 2010 Jun;11(4):656-66.
103. **Pallanti S,** Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. *Journal of Psychopharmacology.* 2010 Jun;24(6):847-53.
104. Bernardi S, **Pallanti S.** Successful duloxetine treatment of a binge eating disorder: a case report. *Journal of Psychopharmacology.* 2010 Aug;24(8):1269-72.
105. **Pallanti S,** Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. *Journal of Neurology.* 2010 Aug;257(8):1362-8.
106. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-BruguÃ M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, **Pallanti S,** Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. *BMC Psychiatry.* 2010;3; 10:67.
107. **Pallanti S.** Augmentation strategies in resistant obsessive-compulsive disorders (OCD), *International Journal of Psychiatry in Clinical Practice* 14, 15-16, 2010-11-01.
108. **Pallanti S,** Bernardi S, Allen A, Hollander E. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. *Journal of Psychopharmacology.* 2010 Dec;24(12):1802-9.
109. **Pallanti S.** Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. *CNS Spectrums.* 2010 Mar;15(3):154-6.
110. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, **Pallanti S,** Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. *Journal of Clinical Psychiatry.* 2011 May;72(5):716-21. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
111. Di Rollo A, **Pallanti S.** Phantom limb pain: low frequency repetitive transcranial magnetic stimulation in unaffected hemisphere. *Case Reports in Medicine.* 2011; 2011:130751.
112. Bernardi S, Faraone SV, Cortese S, Kerridge BT, **Pallanti S,** Wang S, Blanco C. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Psychological*

Medicine. 2011 Aug 16:1-13. *\*Provided study ideas and concept, participated in the drafting and revision of the manuscript, and provided mentorship to first author*

113. **Pallanti S**, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. *Front Psychiatry*. 2011; 2:70.
114. Valenti R, Pescini F, Antonini S, Castellini G, Poggese A, Bianchi S, Inzitari D, **Pallanti S**, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the DSM-IV semi-structured interview. *Acta Neurologica Scandinavica*. 2011 Dec;124(6):390-5. *\*Participated extensively in conception and trial design, acquisition, analysis and interpretation of data, participated in drafting, reviewing and critical revision of the manuscript.*
115. Baldwin DS, Allgulander C, Bandelow B, Ferre F, **Pallanti S**. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. *World Journal of Biological Psychiatry*. 2012; 13(7):510-6.
116. **Pallanti, S.**, Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In *Obsessive-Compulsive Disorder*, J. Zohar (Ed.) <https://doi.org/10.1002/9781119941125.ch5>
117. Moretti S, Arunachalam M, Colucci R, **Pallanti S**, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. *Journal of the European Academy of Dermatology and Venereology*. 2012; 26(7):861-7. *\*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript*
118. **Pallanti S**, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L. rTMS age-dependent response in treatment resistant depressed subjects: a mini-review, *CNS Spectrums* (2012), 17, 24-30.
119. **S. Pallanti**, A. Di Rollo, S. Antonini, E. Hollander and L. Quercioli Low Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement is Independent from Clinical Response, *Neuropsychobiology* 2012 Jun; 65(4):227-35.
120. Moretti S., Arunachalam M., Colucci R., **Pallanti S.**, Kline JA., Berti S., Lotti F., Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. *Journal of the European Academy of Dermatology and Venereology* 2012; 26 (7), 861-867. *\*Participated extensively in conception, drafting, reviewing and critical revision of the manuscript.*
121. **Pallanti S**, Salerno L. Pharmacological treatment and management of attention deficit hyperactivity disorder (ADHD) in adults. *Minerva Psichiatrica* 2013 Dec; 54(4):297-315. ISSN: 1827-1731
122. **Pallanti. S.** The Placebo Effect in Clinical Practice. *American Journal of Psychiatry* 2013 170:8, 931-932
123. Bandinelli F, Prignano F, Bonciani D, **Pallanti S**, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bonghi S, Matucci-Cerinic M. Clinical and demographic

- factors influence on anxiety and depression in early psoriatic arthritis (ePsA). *Clinical and Experimental Rheumatology*. 2012;31(2):318-9. \*Participated extensively in conception, drafting, reviewing and critical revision of the manuscript
124. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In *Obsessive-Compulsive Disorder*, J. Zohar (Ed.) <https://doi.org/10.1002/9781119941125.ch5>
  125. Baldwin DS, **Pallanti S**, Zwanzger P. Developing a European Research Network to Address Unmet Needs in Anxiety Disorders. *Neuroscience and Biobehavioral Reviews*. 2013; 37(10 Pt 1):2312-7. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
  126. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, **Pallanti S**, Pantoni L., Facial Affect Recognition in CADASIL Patients., *Archives of Clinical Neuropsychology* 2013;28(1):65-71. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
  127. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, **Pallanti S**, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. *World Journal of Biological Psychiatry*. 2013;(2): 121-128. \*Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript
  128. **Pallanti S**, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. *Current Psychiatry Reports*. 2013;15(5):354.
  129. Dell'Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, **Pallanti S**, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder, a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *European Neuropsychopharmacology*. 2013 Aug; 23(8):865-71. \*Participated extensively in conception and trial design, acquisition and analysis of data, participated in drafting, reviewing and critical revision of the manuscript
  130. **Pallanti S**, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral Addictions: From Behavioral Dimensions to the Research Domain Criteria Based Target. *Current Psychopharmacology*, 2013; 2(3):183-189.
  131. Marras A, **Pallanti S**. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. *Case Reports in Psychiatry*. 2013; 2013:930304.
  132. **Pallanti S**, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. *CNS Spectrums*. 2014; 19(1):50-61.
  133. Carelli R, **Pallanti S**. Streptococcal infections of skin and PANDAS. *Dermatologic Therapy*. 2014 Jan; 27(1):28-30.

134. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, **Pallanti S**. Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. *CNS Spectrums*. 2014; 9(4):340-6.
135. Van Ameringen S, Simpson W, Patterson B, Dell'Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, **Pallanti S**, Stein DJ, Zohar J. Pharmacological treatment strategies in obsessive-compulsive disorder: A cross-sectional view in nine international OCD centers. *Journal of Psychopharmacology* 2014; 28(6):596-602. \*Participated extensively in conception and trial design, authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript
136. Di Rubbo R., Sogaro E., **Pallanti, S**. Communicative evolutive psychotherapy adapted for the psychodynamic group setting in the treatment of pathological interpersonal dynamics of identity. *Dynamische Psychiatrie*. 2013; 46(3): 204-233.
137. **Pallanti S**, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorders. *Expert opin Emerg Drugs*, 2014 Mar; 19(1):66-77.
138. **Pallanti S**, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: An exploratory study. *J Affect Disord*. 2014; 157:66-71.
139. **Pallanti S**, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. *Eur Neuropsychopharmacol*. 2014; 24(3):375-380.
140. Van Ameringen M, Simpson W, Patterson B, Dell'Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, **Pallanti S**, Stein DJ, Zohar J. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. *J Psychopharmacol*. 2014 Jun;28(6):596-602. doi: 10.1177/0269881113517955. Epub 2014 Jan 15. PMID: 24429223.
141. **Pallanti S**, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to neurocircuits: what we can learn from DBS? The case of obsessive-compulsive disorder. *J. Psychopathol*. 2014; 20:27-32.
142. Aguglia E, Biggio G, Signorelli MS, Mencacci C; **Steering Committee on behalf of the STIMA-D Investigators**. Italian Study on Depressive Disorders (STudio Italiano MAattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. *Pharmacopsychiatry*. 2014 May;47(3), 105-10. \*Member: **Pallanti S**. \*Acquisition of data
143. **Pallanti S**, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary data. *International Journal of Psychiatry in Clinical Practice*. 2014; 18(4):255-60.
144. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven\_Wetzler A, Altamura AC, Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, **Pallanti S**, Stein DJ. Comorbidity in obsessive-compulsive disorder (OCD): a report from the International

- College of Obsessive-Compulsive Spectrum Disorder (ICOCS). *Comprehensive Psychiatry*. 2014;55(7):1513-9. \*Participated extensively in conception and trial design, drafting, reviewing and critical revision of the manuscript
145. **Pallanti S**, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. *Expert Opin Pharmacother*. 2014;15(17):2543-52.
  146. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M; **Italian Network for Research on Psychoses**. The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. *Schizophrenia Research*. 2014; 159(1):144-50. \*Member: **Pallanti S**.
  147. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry*. 2014; 13(3):275-87. \*Member: **Pallanti S**. \*Acquisition of data
  148. Cantisani, A., Grassi, G., Pagano, L., Comanducci, A., Lanzo, G., Amantini, a., Grippo, a., Salerno, L., **Pallanti, S**. Neurophysiological alterations in adults with attention deficit/hyperactivity disorder: an event-related potential study. *European Neuropsychopharmacology* 24:S714-S715 · October 2014. DOI: 10.1016/S0924-977X(14)71151-4
  149. Grassi G, Godini L, Grippo A, Piccagliani D, **Pallanti S**. Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. *Brain Stimulation*. 2015; 8(1):160-1.
  150. **Pallanti S**, Salerno L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. *World Journal of Psychiatry*. 2015;5(1):47-55.
  151. Grassi, G., **Pallanti, S**. Citalopram Pulse-Loading for Treatment-Resistant Obsessive-Compulsive Disorder: Preliminary Data from an Open-Label Trial. *European Neuropsychopharmacology*, Volume 26, Issue 5, 2016, Pages 898-899, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2015.06.034>.
  152. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, **Pallanti S**, Van Ameringen M, Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from International College of Obsessive Compulsive Spectrum Disorder (ICOCS). *CNS Spectrums*. 2015; 20(5):469-73. \*Participated extensively in conception, participated in drafting, reviewing and critical revision of the manuscript
  153. Uzunova G, **Pallanti S**, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorder: Implications for interventions and therapeutics. *World Journal of*

- Biological Psychiatry. 2015; 15:1-13. \*Authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript
154. **Pallanti, S.**, Grassi G, Marras A, Hollander E. Can we modulate obsessive-compulsive networks with neuromodulation? *J Psychopatol*, 21:262-265.
  155. **Pallanti, S.**, Marras A, Grassi G. Outcomes with neuromodulation in obsessive-compulsive disorder. *Psych Annals*, 45(6):316-320.
  156. **Pallanti, S.**, Marras, A. Transcranial Magnetic Stimulation Treatment for Motor Symptoms in Parkinson's Disease: A Review of Two Decades of Studies. *Journal of Alzheimer's Disease & Parkinsonism*. 05. 10.4172/2161-0460.1000191.
  157. **Pallanti, S.**, Marras, A. Transcranial Magnetic Stimulation in Alzheimer's Disease: A Review of Investigational and Therapeutic Findings. *J Alzheimers Dis Parkinsonism* 5:187. doi:10.4172/2161-0460.1000187
  158. Grassi, G., Molesti E., Lori S., Pallanti S., Cheli E., Marras A. "OR-38: neuromodulation of decision-making networks with alphaEEG-guided repetitive transcranial magnetic stimulation: preliminary results from a pilot study." *Journal of Behavioral Addictions*, vol. 5, no. S1, 2016, p. 17+.
  159. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, **Pallanti S**, Hollander E, Van Balkom A J, New treatment models for compulsive disorders. *European Neuropsychopharmacology* 2016; 26(5):877-84. \*Participated extensively in conception, acquisition of data, authorship of sections of the manuscript
  160. Grassi G, **Pallanti S**, Righi L, Figeo M, Mantione M, Denys D, Piccagliani D, Rossi A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive disorder. *Journal of Behavioral Addiction* 2015;4(4):263-72. \**Provided study ideas, participated in the drafting, reviewing and revision of the manuscript, and provided mentorship to first author*
  161. **Pallanti S**, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review, and pilot open-label trial. *Journal of Psychopharmacology*. 2016; 30(6):568-78.
  162. Menchon JM, Van Ameringen M, Dell'Osso B, Denys D, Figeo M, Grant JE, Hollander E, Marazziti D, Nicolini H, **Pallanti S**, Ruck R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Keane R, Pasquini M, Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. *International Journal of Psychiatry in Clinical Practice*. 2016;20(3):204-8. \*Participated extensively in conception and trial design, acquisition of data and in drafting
  163. Marras A, Fineberg N, **Pallanti S**. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. *CNS Spectrums*. 2016;21(4):324-33.

164. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, **Pallanti S**, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. *World Journal of Biological Psychiatry*. 2016; 15:1-53. \*Participated extensively in conception and trial design, acquisition, authorship of sections of the manuscript
165. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. *J Psychiatr Res*. 2016 Dec;83:240-248. doi: 10.1016/j.jpsychires.2016.09.012. Epub 2016 Sep 14. PMID: 27665536.
166. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, **Pallanti S**, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *International Journal of Psychiatry in Clinical Practice*. 2016; 19:1-8. \*Participated extensively in conception and trial design, acquisition of data and in drafting
167. **Pallanti S**. ICD and DSM: Neuroplasticity and Staging are still missing. *CNS Spectrums*. 2016 Aug;21(4):276-8.
168. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; **Italian Network for Research on Psychoses**. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. *Schizophr Res* 2016; 175(1-3):154-60. \*Member: **Pallanti S**. \*Participated extensively in conception and trial design, acquisition, analysis of data, reviewing and critical revision of the manuscript
169. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigaud M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; **Italian Network for Research on Psychoses**. Social cognition in people with schizophrenia: a cluster-analytic approach. *Psychol Med* 2016 Oct;46(13):2717-2729 \*Member: **Pallanti S**. \*Participated extensively in conception and trial design, acquisition, participated in drafting, reviewing and critical revision of the manuscript
170. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE, Hollander E, Marazziti D, Nicolini H, **Pallanti S**, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. *Int J Psychiatry Clin Pract*. 2016 Sep;20(3):204-8. \*Participated extensively in

conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript

171. Giordano F, Cavallo M, Spacca B, **Pallanti S**, Tomaiuolo F, Pieraccini F, Fagiolini A, Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. *Stereotact Funct Neurosurg.* 2016 Nov 1;94(6):371-378. \*Participated extensively in conception and trial design, acquisition of data and in drafting
172. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, **Pallanti S**, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figeo M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *Int J Psychiatry Clin Pract.* 2016 Nov;20(4):210-7. \*Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript
173. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, **Pallanti S**. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. *J Psychiatr Res.* 2016 Dec; 83:240-248.
174. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grünblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Ströhle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. *World J Biol Psychiatry.* 2017 Apr;18(3):162-214. doi: 10.1080/15622975.2016.1190867. Epub 2016 Jul 15. PMID: 27419272; PMCID: PMC5341771.
175. Chiariello F, Spitoni S, Hollander E, **Pallanti S**. An expert opinion on PANDAS/PANS: highlights and controversies. *International Journal of Psychiatry in Clinical Practice* 2017; 1-8 Published online: 13 Feb 2017
176. Salerno L, Makris N, **Pallanti S**. Raadult ADHD: a key feature. *Journal of Psychopathology* 2016; 22:135-140.
177. **Pallanti S**. Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. *The World Journal of Biological Psychiatry World J Biol Psychiatry.* 2017 Apr;18(3):162-214.
178. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, **Pallanti S**, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figeo M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). *CNS Spectr.* 2017 Mar 16:1-8.



179. Dell'Osso B, Marazziti D, Albert U, **Pallanti S**, Gambini G, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. *Int J Psychiatry Clin Pract.* 2017 Jun;21(2):156-159.
180. Salerno L, Burian I, **Pallanti S**. A new generation rating scale for depression: Reliability and Validity of the Italian version of Symptoms of Depression Questionnaire (SDQ), an RDoC-oriented depression comprehensive assessment. *Journal of Psychopathology*, 2017 23:1-12.
181. Grassi, G., Pacini, S., Cecchelli C., **Pallanti, S**. Enhancing inhibition processes during cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive transcranial magnetic stimulation. S1009. *European Neuropsychopharmacology*, 2017
182. Grassi, G., & **Pallanti, S**. (2017). Common Neural Networks Between OCD and Behavioural Addictions: Is LCD a Behavioural Addiction? *European Psychiatry*, 41(S1), S21-S22. Doi:10.1016/j.eurpsy.2017.01.120
183. Lusicic A, Schruers KR, **Pallanti S**, Castle DJ. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. *Neuropsychiatr Dis Treat.* 2018 Jun 29;14:1721-1736. doi: 10.2147/NDT.S121140. PMID: 29988759; PMCID: PMC6029675.
184. Micheli L., Spitoni S, Di Cesare Mannelli L., Billa A.R., **Pallanti S**. Bacopa Monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. 01 April 2020 <http://10.1002/ptr.6684>
185. Grassi G, Figeo M, Ooms P, Righi L, Nakamae T, **Pallanti S**, Schuurman R, Denys D. Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual. *CNS Spectr.* 2018 Jun 4:1-7
186. Burchi E, **Pallanti S**. Antibiotics for PANDAS? Limited Evidence: Review and Putative Mechanisms of Action. *Prim Care Companion CNS Disord.* 2018 May 3;20(3).
187. Burchi E, **Pallanti S**. Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and Their Treatment Implications. *Curr Neuropharmacol.* 2018 Apr 26.
188. Fineberg NA, Chamberlain SR, Menchon J, Demetrovics D, Grünblatt E, **Pallanti S**, Carmi L, Billieux J, King D, Delloso B, Van Ameringen M, Hall N, Potenza M, Hollander E, Zohar J and the COST Action EU-PUI Network. Manifesto for a European Research Network into Problematic Usage of the Internet. 2018, in submission.
189. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, **Pallanti S**; COST Action Network, Chamberlain SR. Version 2. Manifesto for a European research network into Problematic Usage of the Internet. *Eur Neuropsychopharmacol.* 2018 Nov;28(11):1232-1246. Doi: 10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID: 30509450

190. Burchi E, Hollander E, **Pallanti S**. From Treatment Response to Recovery: A Realistic Goal in OCD. *Int J Neuropsychopharmacol*. 2018 Nov 1;21 (11):1007-1013. doi: 10.1093/ijnp/pyy079. PMID:30184141
191. Grassi G, **Pallanti S**. *Expert Opinion Pharmacother*. 2018 Oct;19(14):1541-1550. Doi:10.1080/14656566.2018.1528230. Epub 2018 Oct 15. PMID:3021070
192. Sali L, Ventura L, Grazzini G, Borgheresi A, Delsanto S, Falchini M, Mallardi B, Mantellini P, Milani S, **Pallanti S**, Zappa M, Mascialchi M. Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial. *Eur Radiol*. 2018 Nov 6. doi: 10.1007/s00330-018-5808-1. [Epub ahead of print] PMID:30402705
193. Scarpino, M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu Cesarina, Bastianelli M, Occupati B, Lanzi C, **Pallanti S**, Amantini A, Mannaioni G, Grippo A. Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the Magne Tox study): A study protocol for a randomized placebo-controlled pilot trial. *Neurophysiologie Clinique*, 10 2018
194. Grassi, G., **Pallanti, S**. Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults, *Expert Opinion on Pharmacotherapy*, 19:14, 1541-1550, DOI: [10.1080/14656566.2018.1528230](https://doi.org/10.1080/14656566.2018.1528230) 2018
195. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, **Pallanti S**; COST Action Network, Chamberlain SR., Manifesto for a European research network into Problematic Usage of the Internet. *Eur Neuropsychopharmacol*. 2018 Nov;28(11):1232-1246. doi: 10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID:30509450
196. Scarpino M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu C, Bastianelli M, Occupati B, Lanzi C, **Pallanti S**, Amantini A, Mannaioni G, Grippo A., Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the MagneTox Study): A study protocol for a randomized placebo-controlled pilot trial. *Neurophysiol Clin*. 2019 Feb;49(1):1-9. doi: 10.1016/j.neucli.2018.10.002. Epub 2018 Oct 26. PMID:30712533
197. Grassi, G., Pacini, S., Cecchelli, C., **Pallanti, S**. Enhancing Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with Transcranial Magnetic Stimulation: A proof of concept. *European Neuropsychopharmacology*, Volume 28, Issue 6, 2018, Pages 766-767, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2017.10.008>.
198. Grassi G., Makris N., **Pallanti S**. Olfaction in gambling disorder: an exploratory study. *Journal of Behavioral Addictions*. ICBA2018 / April 23–25, 2018 / Cologne, Germany. Vol 7., Supplement 1. [www.academai.com](http://www.academai.com)
199. Fineberg NA, Dell'Osso B, Albert U, Maina G, Geller D, Carmi L, Sireau N, Walitza S, Grassi G, **Pallanti S**, Hollander E, Brakoulias V, Menchon JM, Marazziti D, Ioannidis

- K, Apergis-Schoute A, Stein DJ, Cath DC, Veltman DJ, Van Ameringen M, Fontenelle LF, Shavitt RG, Costa D, Diniz JB, Zohar J., Early intervention for obsessive compulsive disorder: An expert consensus statement. *Eur Neuropsychopharmacol.* 2019 Feb 14. pii: S0924-977X(19)30159-2. doi: 10.1016/j.euroneuro.2019.02.002. [Epub ahead of print] PMID:30773387
200. Hollander E., Van Ameringen M., Nicolini H., Zohar J., **Pallanti S.**, Nezhgoverova V., Fineberg N. E. 01.01 Pharmacological Treatment of resistant OCD. *European Neuropsychopharmacology*, 2019 vol29, S32, Elsevier
201. Marras A., Gavazzi G., Grassi G., Rathi Y., Mascalchi M., Makris N., Camprodon J.A., **Pallanti S.** Abstract59: Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation. *Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation.* Elsevier. 2019 Mar 1., Vol 12, issue 2, e21.
202. Salerno L., Ramat S., Solari G, Grassi G., **Pallanti S.** Parkinson's Disease with Impulse Control Disorders: Higher Prevalence (Frequency) of Symptoms of Attention Deficit Hyperactivity Disorder *International Journal of Clinical Psychiatry* 2019, 7(1): 1-7 DOI: 10.5923/j.ijcp.20190701.01
203. Burchi E., Makris N., Lee MR., **Pallanti S.**, Hollander E. Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. 2019, *Front. Behav. Neurosci.* | doi: 10.3389/fnbeh.2019.00070
204. Sacchetti, E. **Pallanti, S.** Bowden-Jones, H. (2019). Archives of Behavioral Addictions: A new journal for a new era. *Archives of Behavioral Addictions*, 1(1). doi:10.30435/ABA.01.2019.01
205. Grassi G., Makris N., **Pallanti S.** Addicted to compulsion: assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. *CNS Spectr.* 2019 May 20:1-10. doi: 10.1017/S1092852919000993. [Epub ahead of print] PMID:31106718
206. Dell'Osso B., Vismara M., Benatti B., Cirnigliaro G., Grancini B., Fineberg N., Van Ameringen M., Hollander E., Stein D., Menchon JM., Rodriguez C., Nicolini H., Lanzagorta N., **Pallanti S.**, Grassi G., Lochner C., Marazziti D., Hranov G., Karamustafalioglu O., Hranov L., Zohar J. Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). *CNS Spectrums.* doi 10.1017/S1092852919001068 Published online: 27 May 2019
207. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, **Pallanti S.**, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol.* 2019 Jun 26. pii: S0924-977X (19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub ahead of print] Review. PMID:31255396
- 208.** Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kasper, S., **Pallanti S.**, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol.* 2019 Sep;29(9):1061-1062. doi:

10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. No abstract available.  
PMID:31371104

209. Kooij JJS, Bijenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, Thome J, Dom G, Kasper S, Nunes FC, Stes S, Mohr P, Leppamaki S, Casas M, Bobes J, Mccarthy JM, Richarte V, Kjems PA, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipson A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkeiwicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, **Pallanti S**, Young S, Bejerot S, Lehtonen T, Kustow J, Muller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Felegyhazy Z, Garcia-Portilla MP, Asherson P. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. *Eur Psychiatry* 2019 Feb; 56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16.
210. **Pallanti, S.** (2018). Meet our New Field Editor. *CNS Spectrums*, 23(6), 423-423. doi:10.1017/S1092852918001530
211. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, **Pallanti S**, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur Neuropsychopharmacol.* 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27. PMID: 31255396.
212. Fineberg N.A., Van Ameringen M., Drummond L, Hollander E., Stein D.J. Geller D., Walitza S., **Pallanti S.**, Pellegrini L., Zohar J., Rodriguez C.I., Menchon J.M., Morgado P., Mpavaenda D., Fontenelle L.F., Feusner J.D., Grassi G., Lochner C., Veltman D.J., Sireau N., Carmi L., Adam D., Nicolini H., Dell'Osso B. cu obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive. Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Doi.org/10.1016/j.comppsy.2020.152174. 0010-440X/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)
213. Fontenelle LF, Oldenhof E, Eduarda Moreira-de-Oliveira M, Abramowitz JS, Antony MM, Cath D, Carter A, Dougherty D, Ferrão YA, Figuee M, Harrison BJ, Hoexter M, Soo Kwon J, Küelz A, Lazaro L, Lochner C, Marazziti D, Mataix-Cols D, McKay D, Miguel EC, Morein-Zamir S, Moritz S, Nestadt G, O'Connor K, **Pallanti S**, Purdon C, Rauch S, Richter P, Rotge JY, Shavitt RG, Soriano-Mas C, Starcevic V, Stein DJ, Steketee G, Storch EA, Taylor S, van den Heuvel OA, Veale D, Woods DW, Verdejo-Garcia A, Yücel M. A Transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. *Aust N Z J Psychiatry.* 2020 May 4:4867420912327. doi: 10.1177/0004867420912327. [Epub ahead of print] PMID: 32364439
214. Benatti B, Ferrari S, Grancini B, Girone N, Briguglio M, Marazziti D, Mucci F, Dell'Osso L, Gambini O, Demartini B, Tundo A, Necci R, De Berardis D, Galentino R, De Michele S, Albert U, Rigardetto S, Maina G, Grassi G, **Pallanti S**, Amerio A, Amore M, Priori A, Servello D, Viganò C, Bosi M, Colombo A, Porta M, Dell'Osso B. Suicidal

ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. *CNS Spectr.* 2020 May 6:1-8. doi: 10.1017/S1092852920001157. [Epub ahead of print] PMID: 32372727

215. Galderisi S, Rucci P, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Bozzatello P, Bucci P, Carpinello B, Collantoni E, Cuomo A, Dell'Osso L, Di Fabio F, di Giannantonio M, Gibertoni D, Giordano GM, Marchesi C, Monteleone P, Oldani L, Pompili M, Roncone R, Rossi R, Siracusano A, Vita A, Zeppegno P, Maj M; **Italian Network for Research on Psychoses\***. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. \*Member: **Pallanti, S.** *World Psychiatry.* 2020 Feb;19(1):81-91. doi: 10.1002/wps.20700.PMID: 31922687
216. Fontenelle, L. F., Oldenhof, E., Eduarda Moreira-de-Oliveira, M., Abramowitz, J. S., Antony, M. M., Cath, D. C., Carter, A., Dougherty, D., Ferrão, Y. A., Figuee, M., Harrison, B. J., Hoexter, M., Soo Kwon, J., Küelz, A., Lazaro, L., Lochner, C., Marazziti, D., Mataix-Cols, D., McKay, D., Miguel, E.C., Morein-Zamir, S., Moritz, S., Nestadt, G., O'Connor, K., **Pallanti, S.**, Purdon, C., Rauch, S., Richte, P., Rotge, J.Y., Shavitt, R.G., Soriano-Mas, C., Stein, D.J., Steketee, G., Sorch, E.A., Taylor, S., Van den Heuvel, O.A., Veale, D., Woods, D.W., Verdejo-Garcia, A., Yucel, M. The International OCDs Neuroscience Consensus Group (2020). A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. *Australian & New Zealand Journal of Psychiatry*, 54(7), 719-731. <https://doi.org/10.1177/0004867420912327>
217. Sali, L., Ventura, L., Grazzini, G., Borgherese, A., Delsanto, S., Falchini, M., Mallardi, B., Mantellini, P., Milani, S., **Pallanti, S.**, Zappa M., Mascialchi M. Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial. *Eur Radiol* **29**, 2457–2464 (2019). <https://doi.org/10.1007/s00330-018-5808-1>
218. Fineberg, Naomi A., Hollander, Eric, **Pallanti, Stefano**, Walitza, Susanne Grünblatt, Edna<sup>g,h,i</sup>; Dell'Osso, Bernardo Maria<sup>j,k,l,m</sup>; Albert, Umberto<sup>n</sup>; Geller, Daniel A.<sup>o</sup>; Brakoulias, Vlasios<sup>p,q</sup>; Janardhan Reddy, Y.C.<sup>r</sup>; Arumugham, Shyam Sundar<sup>r</sup>; Shavitt, Roseli G.<sup>s</sup>; Drummond, Lynne<sup>t</sup>; Grancini, Benedetta<sup>b,j</sup>; De Carlo, Vera<sup>b,j</sup>; Cinosi, Eduardo<sup>a,b</sup>; Chamberlain, Samuel R.<sup>u,v</sup>; Ioannidis, Konstantinos<sup>u,v</sup>; Rodriguez, Carolyn I.<sup>k,w</sup>; Garg, Kabir<sup>b</sup>; Castle, David<sup>x</sup>; Van Ameringen, Michael<sup>y,z</sup>; Stein, Dan J.<sup>aa</sup>; Carmi, Lior<sup>bb,cc</sup>; Zohar, Joseph<sup>bb,dd</sup>; Menchon, Jose M.<sup>ee</sup> Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders, *International Clinical Psychopharmacology*: July 2020 - Volume 35 - Issue 4 - p 173-193 doi: 10.1097/YIC.0000000000000314
219. **Pallanti S.** Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. *Compr.Psychiatry.*2020;100:152184.Doi: 10.1016/j.comppsy.2020.152184
220. **Pallanti S,** Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health

sequelae [published online ahead of print, 2020 Aug 15]. *J Psychiatr Res.* 2020;130:215-217. doi: 10.1016/j.jpsychires.2020.08.008

221. Netto, V.D.M., Flores, C., **Pallanti, S.** Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults, *Journal of Psychiatric Practice*: September 2020 - Volume 26 - Issue 5 - p 383-393. doi: 10.1097/PRA.0000000000000499
222. Gaur S, **Pallanti S.** Treatment Outcomes in an Adult Attention Deficit Hyperactivity Disorder Clinic with a Focus on Executive Functioning and Sluggish Cognitive Tempo. *Cureus* 12(8): e9814. doi: 10.7759/cureus.9814
223. **Pallanti, S.**, Porta, F., Salerno, L., Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities, *Journal of Psychiatric Research*, 2020, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2020.10.027>.  
(<http://www.sciencedirect.com/science/article/pii/S002239562031030X>)
224. Castro-Calvo, J., King, D. L., Stein, D. J., Brand, M., Carmi, L., Chamberlain, S. R., Demetrovics, Z., Fineberg, N. A., Rumpf, H.-J., Yücel, M., Achab, S., Ambekar, A., Bahar, N., Blaszczynski, A., Bowden-Jones, H., Carbonell, X., Chan, E. M. L., Ko, C.-H., de Timary, P., Dufour, M., Grall-Bronnec, M., Lee, H. K., Higuchi, S., Jimenez-Murcia, S., Király, O., Kuss, D. J., Long, J., Müller, A., **Pallanti, S.**, Potenza, M. N., Rahimi-Movaghar, A., Saunders, J. B., Schimmenti, A., Lee, S.-Y., Siste, K., Spritzer, D. T., Starcevic, V., Weinstein, A. M., Wölfling, K., and Billieux, J. (2021) Expert appraisal of criteria for assessing gaming disorder: An international Delphi study. *Addiction*, <https://doi.org/10.1111/add.15411>.
225. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., **Pallanti, S.**, Racagni, G., Singh, S. *Future Neurology* 2020 15:4. 30 Nov 2020 <https://doi.org/10.2217/fnl-2020-0012>
226. Micheli, L, Spitoni, S, Di Cesare Mannelli, L, Bilia, AR, Ghelardini, C, **Pallanti, S.** Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. *Phytotherapy Research*. 2020; 34: 2331– 2340. <https://doi.org/10.1002/ptr.6684>
227. Fineberg, N. A., Van Ameringen, M., Drummond, L., Hollander, E., Stein, D. J., Geller, D., Walitza, S., **Pallanti, S.**, Pellegrini, L., Zohar, J., Rodriguez, C. I., Menchon, J. M., Morgado, P., Mpavaenda, D., Fontenelle, L. F., Feusner, J. D., Grassi, G., Lochner, C., Veltman, D. J., Sireau, N., ... Dell'Osso, B. (2020). How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. *Comprehensive psychiatry*, 100, 152174. <https://doi.org/10.1016/j.comppsy.2020.152174>
228. Uzunova, G., **Pallanti, S.**, Hollander, E. (2021) Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase, *International Journal of Psychiatry in Clinical Practice*, DOI: [10.1080/13651501.2021.1887264](https://doi.org/10.1080/13651501.2021.1887264)

229. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Bastianelli M, Occupati B, Gori F, Del Vecchio A, Ercolini A, Pascolo S, Cimino V, Meneghin N, Fierini F, D'Anna G, Innocenti M, Ballerini A, **Pallanti S**, Grippo A, Mannaioni G. A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. *PLoS One*. 2021 Nov 16;16(11):e0259860. doi: 10.1371/journal.pone.0259860. PMID: 34784373.
230. Nezgovorova, V., Ferretti, C.J., **Pallanti, S.**, Hollander, E. Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder, *Journal of Psychiatric Research*, 2021, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2021.11.025>.
231. **Pallanti, S.**, Marras, A., & Makris, N. (2021). A Research Domain Criteria Approach to Gambling Disorder and Behavioral Addictions: Decision-Making, Response Inhibition, and the Role of Cannabidiol. *Frontiers in psychiatry*, 12, 634418. <https://doi.org/10.3389/fpsy.2021.634418>
232. Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E, Ioannidis K, Pallanti S, Chamberlain SR, Rossell SL, Veale D, Wilhelm S, Van Ameringen M, Dell'Osso B, Menchon JM, Fineberg NA. Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders **Network of the European College of Neuropsychopharmacology** (Pallanti, S.) *Int Clin Psychopharmacol*. 2021 Mar 1;36(2):61-75. doi: 10.1097/YIC.0000000000000342. PMID: 33230025; PMCID: PMC7846290.
233. Bentatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, C., Jo, Booil., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti, D., **Pallanti, S.**, Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figeo, M., Drummond, L., Grant, JE., Denys D., Fontenelle LF., Menchon JM., Zohar, J., Pellegrini, L., Rodriguez, C. Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology, *Journal of Psychiatric Research*, Volume 140, 2021, Pages 357-363, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2021.05.054>.
234. Salerno L., **Pallanti S.** COVID-19 Related Distress in Gambling Disorder. *Frontiers in Psychiatry*. VOLUME12. 2021. pp156. <https://www.frontiersin.org/article/10.3389/fpsy.2021.620661>. DOI10.3389/fpsy.2021.620661. ISSN1664-0640
235. Grassi, G., Figeo, M., Stratta, P., Rossi, A., & **Pallanti, S.** Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016), *Journal of Behavioral Addictions J Behav Addict*, 5(3), 398-400. Retrieved Apr 9, 2021, from <https://akjournals.com/view/journals/2006/5/3/article-p398.xml>
236. **Pallanti S**, Salerno L. ADHD: the dark side of Eating Disorders. *Evidence-based Psychiatric Care* 2016;2;24-31, [http:// www.evidence-based-](http://www.evidence-based-)

237. Benatti, B., Girone, N., Conti, D., Cafaro, R., Vigano, C., Briguglio, M., Marazziti, D., Mucci, F., Gambini, O., Demartini, B., Tundo, A., Necci, R., De Berardis, D., Galentino, R., De Michele, S., Balestrino, R., Albert U., Rogardetto S., Mania, G., Grassi, G., **Pallanti, S.**, Amerio, A., Aguglia, A., Presta, D., Amore, M., Priori, A., Servello, D., Porta, M., Dell'Osso, B. (2021). Assessing response, remission and treatment resistance in patients with Obsessive-Compulsive Disorder with and without Tic Disorders: results from a multicenter study. *CNS Spectrums*, 1-22. Doi:10.1017/S109285292100081X
238. **Pallanti, S.**, Marras, A., Dickson, S. L., Adan, R. A. H., Vieta, E., Dell'Osso, B., Arango, C., Fusar-Poli, P., Soriano-Mas, C., Carmi, L., Meyer-Lindenberg, A., Zohar, J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty, *European Neuropsychopharmacology*, Volume 52, 2021, Pages 72-83, ISSN 0924-977X, <https://doi.org/10.1016/j.euroneuro.2021.07.002>. (<https://www.sciencedirect.com/science/article/pii/S0924977X21002728>)
239. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander, E., Ioannidis, K., **Pallanti, S.**, Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm, S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. *International clinical psychopharmacology*, 36(2), 61–75. <https://doi.org/10.1097/YIC.0000000000000342>
240. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., **Pallanti, S.**, Racagni, G., Singh, S. Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. *Future Neurology* 2020 15:4. 30 Nov 2020 <https://doi.org/10.2217/fnl-2020-0012>
241. Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, **Pallanti S**, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. *Mol Psychiatry*. 2021 Dec 15. doi: 10.1038/s41380-021-01381-x. Epub ahead of print. PMID: 34907394.
242. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander, E., Ioannidis, K., **Pallanti, S.**, Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm, S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the



International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. *International clinical psychopharmacology*, 36(2), 61–75. <https://doi.org/10.1097/YIC.0000000000000342>

243. **Pallanti S.** Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non Invasive Brain Stimulation (NIBS) in the era of brain connectivity. *Eur Neuropsychopharmacol.* 2021 Apr;45 38. doi:10.1016/j.euroneuro.2021.03.004. PMID: 33745763.
244. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, **Pallanti S.**, Mannaioni, G. et.al. (2021) A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. *PLOS ONE* 16(11): e0259860. <https://doi.org/10.1371/journal.pone.0259860>
245. Benatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, Booil Jo, C., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti, D., **Pallanti, S.**, Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figuee, M., L., Drummond, Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM., Zohar, J., Pellegrini, L., Rodriguez, CI. Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology, *Journal of Psychiatric Research*, Volume 140, 2021, Pages 357-363, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2021.05.054>.
246. Benatti, B., Ferrari, S., Grancini, B., Girone, N., Briguglio, M., Marazziti, D., **Pallanti S.**, Dell'Osso, B. et.al. (2021). Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: Results of a multicenter Italian study. *CNS Spectrums*, 26(4), 354-361. doi:10.1017/S1092852920001157
247. **Pallanti, S.**, Makris, N., Camprodon, J., Rathi, Y., Salerno, L., Marras, A., & Gavazzi, G. (2021). P. 0611 Theta burst stimulation of the pre-supplementary motor area in gambling disorder: preliminary data on gambling severity and clinical global impression. *European Neuropsychopharmacology*, 53, S449.
248. Van Ameringen, M., Patterson, B., Turna, J., Lethbridge, G., Bergmann, C. G., Lamberti, N., **S Pallanti**, G Grassi, M Vismara, Umberto Albert, R Gedanke Shavitt, E Hollander, J Feusner, CI Rodriguez, Pedro Morgado Dell'Osso, B. (2022). Obsessive-compulsive disorder during the COVID-19 pandemic. *Journal of Psychiatric Research*.
249. Benatti B., Girone N., Celebre L., Vismara, M., Hollander, E., Fineberg, NA., Stein, DA., Nicolini, H., Lanzagorta, N., Marazziti, D., **Pallanti, S.**, Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figuee, M., Drummond, LM., Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM., Zohar, J., Rodriguez, CI., Dell'Osso, B. The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network, *Comprehensive Psychiatry*, 2022, 152315, ISSN 0010-440X,

<https://doi.org/10.1016/j.comppsy.2022.152315>. PMID: 35483201.  
(<https://www.sciencedirect.com/science/article/pii/S0010440X22000219>)

250. **Pallanti, S.**, Ponzio, M., Grassi, E., Vannini, G., Cauli, G. Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study. *Children* 2022, 9, 755.  
<https://doi.org/10.3390/children9050755>
251. Salerno, L., Grassi, E., Makris, N., Pallanti, S. "A Theta Burst Stimulation on Pre-SMA: Proof-of-Concept of Transcranial Magnetic Stimulation in Gambling Disorder". *J Gamb Stud* (2022). <https://doi.org/10.1007/s10899-022-10129-3>
252. Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias Eriksson, Naomi A. Fineberg, Josef Hättenschwiler, Eric Hollander, Hisanobu Kaiya, Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, José M. Menchón, Euripedes C. Miguel, Hans-Jürgen Möller, Antonio E. Nardi, **Stefano Pallanti**, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang & Joseph Zohar (2022) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders, *The World Journal of Biological Psychiatry*, DOI: [10.1080/15622975.2022.2086295](https://doi.org/10.1080/15622975.2022.2086295)
253. Ilenia Pampaloni, Sabina Marriotti, Enrico Pessina, Claire Fisher, Anusha Govender, Heba Mohammed, Augusta Chandler, Himanshu Tyagi, Lucy Morris, **Stefano Pallanti**, The global assessment of OCD, *Comprehensive Psychiatry*, 2022, 152342, ISSN 0010-440X,  
<https://doi.org/10.1016/j.comppsy.2022.152342>. (<https://www.sciencedirect.com/science/article/pii/S0010440X22000487>)
254. Naomi A. Fineberg, José M. Menchón, Natalie Hall, Bernardo Dell'Osso, Matthias Brand, Marc N. Potenza, Samuel R. Chamberlain, Giovanna Cirnigliaro, Christine Lochner, Joël Billieux, Zsolt Demetrovics, Hans Jürgen Rumpf, Astrid Müller, Jesús Castro-Calvo, Eric Hollander, Julius Burkauskas, Edna Grünblatt, Susanne Walitza, Ornella Corazza, Daniel L. King, Dan J. Stein, Jon E. Grant, **Stefano Pallanti**, Henrietta Bowden-Jones, Michael Van Ameringen, Konstantinos Ioannidis, Lior Carmi, Anna E. Goudriaan, Giovanni Martinotti, Célia M.D. Sales, Julia Jones, Biljana Gjoneska, Orsolya Király, Beatrice Benatti, Matteo Vismara, Luca Pellegrini, Dario Conti, Ilaria Cataldo, Gianluigi M. Riva, Murat Yücel, Maèva Flayelle, Thomas Hall, Morgan Griffiths, Joseph Zohar, *Advances in problematic usage of the internet research – A narrative review by experts from the European network for problematic usage of the internet*, *Comprehensive Psychiatry*, Volume 118, 2022, 152346, ISSN 0010-440X, <https://doi.org/10.1016/j.comppsy.2022.152346>.  
(<https://www.sciencedirect.com/science/article/pii/S0010440X22000529>)
255. Micheli L, Toti A, Lucarini E, Ferrara V, Ciampi C, Olivero G, Pittaluga A, Mattoli L, Pelucchini C, Burico M, Lucci J, Carrino D, Pacini A, **Pallanti S**, Di Cesare Mannelli L and Ghelardini C. (2022) Efficacy of a vegetal mixture composed of Zingiber officinale, Echinacea purpurea, and Centella asiatica in a mouse model of

neuroinflammation: In vivo and ex vivo analysis. *Front. Nutr.* 9:887378. doi: 10.3389/fnut.2022.887378

256. **Pallanti S**, Grassi E, Knotkova H, Galli G. Transcranial direct current stimulation in combination with cognitive training in individuals with mild cognitive impairment: a controlled 3-parallel-arm study. *CNS Spectr.* 2022 Sep 12:1-6. doi: 10.1017/S1092852922000979. Epub ahead of print. PMID: 36093863.
257. Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller HJ, Eriksson E, Fineberg NA, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman MA, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Nardi AE, **Pallanti S**, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD. *World J Biol Psychiatry.* 2022 Jul 28:1-17. doi: 10.1080/15622975.2022.2086296. Epub ahead of print. PMID: 35900217.
258. Bandelow B, Allgulander C, Baldwin DS, Costa DLDC, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg NA, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim YK, Inoue T, Lim L, Masdrakis V, Menchón JM, Miguel EC, Möller HJ, Nardi AE, **Pallanti S**, Perna G, Rujescu D, Starcevic V, Stein DJ, Tsai SJ, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. *World J Biol Psychiatry.* 2022 Jul 28:1-39. doi: 10.1080/15622975.2022.2086295. Epub ahead of print. PMID: 35900161.
259. **Pallanti S.**, Di Ponzio, M., Makris, N., Kubicki, M. Theta-Burst Stimulation over the pre-Supplementary Motor Area in Schizophrenia and comorbid substance use disorder: Preliminary clinical data. *Annals of Psychiatry and Treatment.* 2022. ISSN:2640-8031. DOI: 10.17352/apt.000042 (<https://doi.org/10.17352/apt.000042>)
260. **Pallanti S.**; Salerno, L. Neurodevelopmental Disorders (NDDs): Beyond the Clinical Definition and Translational Approach. *Children* **2023**, *10*, 99. <https://doi.org/10.3390/children10010099>
261. **Pallanti S**, Di Ponzio M. PANDAS/PANS in the COVID-19 Age: Autoimmunity and Epstein–Barr Virus Reactivation as Trigger Agents? *Children.* 2023; 10(4):648. <https://doi.org/10.3390/children10040648>
262. D'Acquisto, F., D'Addario, C., Cooper, D., **Pallanti S.**, Blacksell, I. Peripheral control of psychiatric disorders: Focus on OCD. Are we there yet? *Comprehensive Psychiatry*, 2023, 152388, ISSN 0010-440X, <https://doi.org/10.1016/j.comppsy.2023.152388>. (<https://www.sciencedirect.com/science/article/pii/S0010440X23000251>)
263. Di Ponzio M, Makris N, Tenerini C, Grassi E, Ragone S, **Pallanti S.** rTMS investigation of resistant Obsessive-Compulsive Related Disorders: Efficacy of

targeting the reward system. *Front Psychiatry*. 2023;13:1035469. Published 2023 Feb 3. doi:10.3389/fpsy.2022.1035469

264. **Pallanti, S.**, Zohar J., Kasper S., Möller HJ, Hollander E. (Under Review). Revisiting GABA Enhancers (Benzodiazepines): A Transdiagnostic and Precision Medicine Approach. *The Lancet Psychiatry*
265. **Pallanti, S.**, Di Ponzio, M. (2023). PANDAS/PANS in the COVID-19 Age: Autoimmunity and Epstein–Barr Virus Reactivation as Trigger Agents? *Children*, 10(4), 648. <https://doi.org/10.3390/children10040648>
266. Batail, J.M., Gaillard, R., Haffen, E., Poulef, E., Sauvaget, A., Szekely, D., Brunelin, J., Bulteau, S., Bubrovsky, M., Smadia, J., Bourla, A., Bouaziz, N., Januel, D., Rotharmel, M., Ams, M., Downar, J., Fitzgerald, P.B., Brunonni, A.R., **Pallanti, S.**, D'Urso, G., Baeken, C., Williams, N.R., Millet, B., Lefaucheur, J.P., Drapier, D. No place in France for repetitive transcranial magnetic stimulation in the therapeutic armamentarium of treatment-resistant depression? Open Access, *Brain Stimulation*, Published May 26, 2023. DOI:<https://doi.org/10.1016/j.brs.2023.05.015>
267. **Pallanti, S.**, Gasic, G.P., Makris, N., Lotti, T., Gerakaris, S. and Grassi, E. 2023. Transcranial magnetic stimulation treatment for dermatillomania: a multidisciplinary approach focused on circuitry and neuroplasticity. *Journal of Applied Cosmetology*. 41, 2 (May 2023), Ahead of print. DOI:<https://doi.org/10.56609/jac.v41i2.280>.
268. **Pallanti, S.**, Camprodon, J.A., Di Ponzio, M., Makris, N. Efficacy of Continuous Theta Burst Stimulation to the Pre-supplementary Motor Area in Gambling Disorder: a Randomized Double-Blind Controlled Trial. *International Journal of Mental Health and Addiction*. <https://doi.org/10.1007/s11469-023-01120-z>
269. Di Ponzio, M., **Pallanti, S.** Deep Transcranial Magnetic Stimulation in combination with symptoms provocation: An effective treatment in patients with treatment-resistant Body Dysmorphic Disorder? *Neuroscience Applied*, 2023, 101137, ISSN 2772-4085,<https://doi.org/10.1016/j.nsa.2023.101137>. (<https://www.sciencedirect.com/science/article/pii/S2772408523001199>)
270. Vreeland, A., Calaprice, D., Or-Geva, N., Frye, R., Agalliu, D., Lachman, H.M., Pittenger, C., **Pallanti, S.**, Williams, K., Ma, M., Thienemann, M., Gagliano, A., Mellins, E.D., Frankovich, J. Post-infectious inflammation, autoimmunity, and OCD: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Disorder (PANS). PMID: 37742615. DOI: 10.1159/000534261. *Dev Neurosci*. 2023 Sep 22.
271. **Pallanti, S.**, Di Ponzio, M., Gavazzi, G., Gasic, G., Besteher, B., Heller, C., Kikinis, R., Makris, N., Kikinis, Z. From 'mental fog' to post-acute COVID-19 syndrome's executive function alteration: Implications for clinical approach, *Journal of Psychiatric Research*, 2023, ISSN 0022-3956, <https://doi.org/10.1016/j.jpsychires.2023.09.017>. (<https://www.sciencedirect.com/science/article/pii/S0022395623004284>)
272. Piga, R., Makris, N., **Pallanti, S.**, Palma, R., Castellani, A., Palmieri, S., Guasparri, M., Piga, P., Bucalossi, M. Orthostatic Pressure, Vessel Pressure and

Neurofunctional Changes: A Correlation Study. London Journal of Medical and Health Research. Pulished on December 5, 2023. LJMHR Volume 23, Issue 12, pp 57 – 69. NLMC Code: WL 140. Great Britain Journals Press.

273. **Pallanti, S.**, Zohar, J., Kasper, S., Moller, HJ., Hollander, E. Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach. Journal of Psychiatric Research, Volume 170, 2024, Pages 65-72, ISSN 0022-3956,<https://doi.org/10.1016/j.jpsychires.2023.11.042>. (<https://www.sciencedirect.com/science/article/pii/S0022395623005575>)
274. Burkauskas, J., Branchi, I., **Pallanti, S.**, Domschke, K. Anxiety in post-covid-19 syndrome –prevalence, mechanisms and treatment. Neuroscience Applied, 2023, 103932, ISSN 2772-4085, <https://doi.org/10.1016/j.nsa.2023.103932>. (<https://www.sciencedirect.com/science/article/pii/S2772408523029149>)
275. Domschke K, Seuling PD, Schiele MA, Bandelow B, Batelaan NM, Bokma WA, Branchi I, Broich K, Burkauskas J, Davies SJC, Dell'Osso B, Fagan H, Fineberg NA, Furukawa TA, Hofmann SG, Hood S, Huneke NTM, Latas M, Lidbetter N, Masdrakis V, McAllister-Williams RH, Nardi AE, **Pallanti S**, Penninx BWJH, Perna G, Pilling S, Pini S, Reif A, Seedat S, Simons G, Srivastava S, Steibliene V, Stein DJ, Stein MB, van Ameringen M, van Balkom AJLM, van der Wee N, Zwanzger P, Baldwin DS. The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline. World Psychiatry. 2024 First published: 12 January 2024, World Psychiatry, Volume 23, Issue 1, February 2024, Pages 113 – 123 <https://doi.org/10.1002/wps.21177>.
276. **Pallanti, Stefano**. The role of benzodiazepines in common conditions: a narrative review focusing on lormetazepam. International Clinical Psychopharmacology: December 27, 2023. | DOI: 10.1097/YIC.0000000000000529
277. J. Burkauskas, I. Branchi, **S. Pallanti**, K. Domschke, Anxiety in post-covid-19 syndrome – prevalence, mechanisms and treatment, Neuroscience Applied, Volume 3, 2024, 103932, ISSN 2772-4085, <https://doi.org/10.1016/j.nsa.2023.103932>. (<https://www.sciencedirect.com/science/article/pii/S2772408523029149>)
278. Allison Vreeland, Denise Calaprice, Noga Or-Geva, Richard E. Frye, Dritan Agalliu, Herbert M. Lachman, Christopher Pittenger, **Stefano Pallanti**, Kyle Williams, Meiqian Ma, Margo Thienemann, Antonella Gagliano, Elizabeth Mellins, Jennifer Frankovich; Postinfectious Inflammation, Autoimmunity, and Obsessive-Compulsive Disorder: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection, and Pediatric Acute-Onset Neuropsychiatric Disorder. *Dev Neurosci* 18 December 2023; 45 (6): 361–374. <https://doi.org/10.1159/000534261>
279. **Pallanti, S.**, Levola, J., Lioumis, P. et al. Treatment of Behavioral Addictions and Substance Use Disorders: a Focus on the Effects of Theta-Burst Stimulation Over the Pre-SMA. Int J Ment Health Addiction (2024). <https://doi.org/10.1007/s11469-024-01261-9>

## Peer-Reviewed Editorials

1. **Pallanti S.** The anxiety-psychosis spectrum. *CNS Spectrums*. 2000 Sep;5(9):22.
2. **Pallanti S.**, Transcultural Observations of Obsessive-Compulsive disorder, *American Journal of Psychiatry*, 165:2, February 2008
3. **Pallanti S.**, Problematic Internet Use: is it more compulsory than rewarding or mood driven? *World Psychiatry*.2010 Jun;9(2):96-7.
4. **Pallanti S.** Transcultural observations of obsessive-compulsive disorder. *American Journal of Psychiatry*. 2008 Feb;165(2):169-70.
5. **Pallanti S.** Problematic Internet use: is it more compulsory than rewarding or mood driven? *World Psychiatry*. 2010 Jun;9(2):96-7.
6. Grassi G, Godini L, Grippo A, Piccagliani D, **Pallanti S.** Enhancing Cognitive-behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. *Brain Stimulation*.2014.10.18.
7. Pasquini M., Brakoulias V., **Pallanti S.** Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders. *Front. Psychiatry* 11:93. doi: 10.3389/fpsyt.2020.00093
8. **Pallanti S.** Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity, *European Neuropsychopharmacology*, Elsevier, Editorial.  
<https://doi.org/10.1016/j.euroneuro.2021.03.004>
9. **Pallanti, S.** (2018). Meet our New Field Editor. *CNS Spectrums*, 23(6), 423-423. doi:10.1017/S1092852918001530
10. Oliva F, di Girolamo G, Salerno L, Pallanti S, Wilson L, Philipsen A. Editorial: Adult ADHD and other psychiatric disorders. *Front Psychiatry*. 2022 Nov 1;13:1058117. doi: 10.3389/fpsyt.2022.1058117. PMID: 36386996; PMCID: PMC9664160.

## Peer-Reviewed Abstracts

1. **Pallanti S.**, Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in schizophrenia. *Biological Psychiatry* 35 (9), 637-638. 1994-05-01.
2. Koran L., Sallee F., **Pallanti S.**, Paiva R., Quercioli L. Intravenous pulse loading of clomipramine in obsessive-compulsive disorder. *Psychopharmacology Bulletin* 32 (3), 466-466. Nov. 1996.
3. Di Russo F., Zaccara G., **Pallanti S.**, Gangemi P., Lori S., Ragazzoni A. Visual event-related potentials in obsessive-compulsive disorders. *Electroencephalography and Clinical Neurophysiology* 103 (1), 211-211, Jul 1997.
4. **Pallanti S.**, Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 203-203, 1999-01-01.

5. Russo F., Zaccara G., Ragazzoni A. **Pallanti S.** Abnormal visual ERPs in obsessive-compulsive deficits in young schizophrenic patients. *Journal of Psychophysiology* 13 (3), 207-207, 1999-01-01.
6. **Pallanti S.**, Quercioli L. Reboxetine in bulimia nervosa: An open study. *Biological Psychiatry* 49 (8), 105S-106S. 2001-04-05.
7. Quercioli L., Bruscoli M., **Pallanti S.** P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. *European Neuropsychopharmacology* 14, S186, 2004-10-31.
8. **Pallanti S.**, Quercioli L. Reboxetine in bulimia nervosa: An open study. *Biological Psychiatry* 49 (8), 105S-106S. 2001-04-05.
9. Quercioli L., Bruscoli M., **Pallanti S.** P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. *European Neuropsychopharmacology* 14, S186, 2004-10-31.
10. **Pallanti S.**, Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E., Noradrenergic function in pathological gambling. *Biological Psychiatry*. 2006;59 (8), 32S-32S.
11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., **Pallanti S.** Punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. *European Psychiatry* 23, S350-S351.
12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A., Zaccara G., **Pallanti S.** P27-7 Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation study. *Clinical Neurophysiology* 121, s265, 2010-20-31.

#### Peer-Reviewed Letters and Commentary

1. Marazziti D, **Pallanti S.** Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. *American Journal of Psychiatry*. 1999 Nov;156(11):1834-5.
2. **Pallanti S.** "Dr. Pallanti Replies." *American Journal of Psychiatry*, 2000 157(5):840-a-840.
3. Hollander E, **Pallanti S.** "5-HT1D Function and Repetitive Behaviors." *American Journal of Psychiatry*, 2001 158(6):972-a-973.
4. **Pallanti S.**, Quercioli L, Hollander E. "Dr. Pallanti and Colleague Reply." *American Journal of Psychiatry*, 2005 162(2): 400-a-401.
5. Faravelli C., **Pallanti S.**, Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and Associates Reply. *American Journal of Psychiatry* 150 (9), 1437-1437. 1993-09-01.
6. Grassi G, Figeo M, Stratta P, Rossi A, **Pallanti S.** Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016). *J Behav Addict*. 2016 Sep;5(3):398-400.

7. Koran LM, Faravelli C, **Pallanti S**. Intravenous clomipramine for obsessive-compulsive disorder. *Journal of Clinical Psychopharmacology* 1994 Jun;14(3):216-8
8. Marazziti D, **Pallanti S**. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. *American Journal of Psychiatry*. 1999 Nov;156(11):1834-5.
9. Hollander E, **Pallanti S**. 5-HT(1D) function and repetitive behaviors. *American Journal of Psychiatry*. 2001 Jun;158(6):972-3.
10. **Pallanti S**, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. *American Journal of Psychiatry*. 1999 May;156(5):796.

#### Peer-Reviewed Book Reviews

1. **Pallanti S**. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. *American Journal of Psychiatry* 1999; 156:1108a-1109.
2. **Pallanti S**. Panic Disorder: Clinical Diagnosis, Management and Mechanism. *American Journal of Psychiatry* 158(7), 1176-a-1177. 2001-07-01. Book Review
3. **Pallanti S**. Panic Disorder: Clinical Diagnosis, Management and Mechanism. *American Journal of Psychiatry* 158(7), 1176-a-1177. 2001-07-01.
4. **Pallanti S**. Review of perfectionism: theory, research and treatment. *American Journal of Psychiatry* 2004, vol.161 (8).

#### Book Chapters

1. **Pallanti S.**, Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C. Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary results. **Imaging of the Brain in Psychiatry and Related Fields**, pp 281-284, Edited by K. Maurer, Springer, 1993
2. **Pallanti, S.** Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647 – 1664, *Neuropsychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology*, Edited by K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002
3. **Pallanti, S.** Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp 1315 – 1329, **Biological Psychiatry**, Edited by H. D’Haenen, J.A. den Boer, P. Willner, John Wiley & Sons Ltd., 2002
4. Sood E, **Pallanti S**, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. *Essential Psychopharmacology*, pp 157-169, Edited by R. Murray, Cambridge University Press, 2002
5. **Pallanti, S.** Pharmacological Treatments, pp 189 – 200, **Pathological Gambling: A Clinical Guide to Treatment**, Edited by J. E. Grant, M. Potenza, American Psychiatric Publishing, 2004



6. **Pallanti, S.** Pathological Gambling, pp 251 – 289, **Clinical Manual of Impulse Control Disorders**, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006
7. **Pallanti, S.** Approaches to treatment resistance, pp. 99-117, **Obsessive Compulsive Disorder: Current Science and Clinical Practice**, Edited by J. Zohar, John Wiley & Sons, LTD, 2012
8. Santoro D., **Pallanti S.** Positron Emission Tomography. Edited by Miscaglia, S. pp.177 – 188. Chapter 7, Pathological Gambling: PET Studies. December 18th 2013 DOI: 10.5772/57537 ISBN: 978-953-51-1213-6 eBook (PDF) ISBN: 978-953-51-7188-1 Copyright year: 2013
9. **Pallanti, S.** Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, **Autism Spectrum Disorders- Phenotypes, Mechanisms and treatment**, Edited by M. Leboyer, P. Chaste, Karger Medical and Scientific Publishers, 2015
10. **Pallanti S,** Ring R, Pascual-Leone A, Hollander E. New Technologies in Autism: Non-invasive Brain Stimulation, **Autism Spectrum Disorders**, Enticott PG, Edited by E. Hollander, D. Fein, P.J. Hagerman. Karger Medical and Scientific Publishers, 2017 [in press]
11. **Pallanti S,** Barns J, Pittenger C, Eisen, J. Incompleteness and Harm Avoidance in OCD. Obsessive-Compulsive Disorder – Phenomenology, Pathophysiology and Treatment, Edited by Pittenger C. Oxford University Press, 2017
12. **Pallanti, S.** Malingering Fictitious Disorder: The Assessment of Competence and (Capacity) and Forensic Aspects., Organs and Living Donors, and Transplantation; The so-called “Biological Testament” pp. 73 – 81, Handbook of Psychiatry and Behavioral Health. Carocci Editori Roma, March 2020
13. Consultant to: Long version of the interdisciplinary evidence- and consensusbased (S3) guideline “Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults” AWMF Registration No. 028-045. Published at AWMF online. Association of Analytical Child and Adolescent Psychotherapists in Germany (Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in Deutschland e. V., VAKJP)
14. Salerno L, Gaur S, Grassi G, **Pallanti S.** Neuromodulation in Attention-Deficit/Hyperactivity Disorder: Toward a Precision Psychiatry Approach Chapter in Bernardo Dell’Osso and Giorgio Di Lorenzo (Eds): Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences, 978-3-030-43355-0, 479307\_1\_En, (9)
15. **Pallanti, S.,** English, A.C. From Exercise to Addiction: The Fitness Era of Image and Performance Enhancement. A chapter in Corazza, O., Dores, A.R. (Eds); The Body in the Mind: Exercise Addiction, Body Image and the Use of Enhancement Drugs. Cambridge University Press, 2023 Paperback 978-1-911623-72-4. ISBN 9781911623724
16. Gaur, S., **Pallanti, S.,** Patankar, A. Behavioral phenotype of ADHD in individuals with a genetic risk for Celiac disease: Recommendations for evaluation. children-2510423 (in press)

17. Vreeland, A., Calaprice, D., Or-Geva, N., Frye, R., Agalliu, D., Lachman, H.M., Pittenger, C., **Pallanti, S.**, Williams, K., Ma, M., Thienemann, M., Gagliano, A., Mellins, E.D., Frankovich, J. Post-infectious inflammation, autoimmunity, and OCD: Sydenham Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Disorder (PANS). DNE-2023-5-3 (in press).

## Books

1. **Pallanti S.**, Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in Silence, La nuova Italia Scientifica (1996)
2. Fossi G., **Pallanti S.**, Manuale di Psichiatria (Manual of Psychiatry), Casa Editrice Ambrosiana, Milano (1993)
3. **Pallanti S.**, Koran L. M., Treatment of OCD Resistant Patients, Airon (2003)
4. **Pallanti S.**, Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by Innova Pharma SpA, Milano
5. Fossi G., **Pallanti S.**, Psichiatria Elementare (Elementary Psychiatry), La Nuova Italia Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008
6. **Pallanti, S.** and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B. Hales, American Psychiatric Publishing. (2010)
7. **Pallanti, S.** and Formosa, A., Stress? No grazie, siamo resiliente, (Stress? No Thank you, We are resilient) Trevisini Editore. (2011)
8. **Pallanti, S.**, Oltre la Schizophrenia (Beyond Schizophrenia) Edra LSWR (2015)
9. Fossi, G., **Pallanti, S.**, Psichiatria Elementare (Elementary Psychiatry), Carocci Editori, First edition 1999, Reprint 2015
10. **Pallanti, S.**, Psichiatria Elementare – Oltre il DSM-5 (Elementary Psychiatry – Beyond DSM -5), Carocci Editori, (2017)
11. **Pallanti S** Salerno L. The Burden of Adult ADHD in Comorbid Psychiatric and Neurological Disorders; Springer International Publishing 2020
12. **Pallanti S** Psichiatria e Salute Comportamentale Carocci Editori 2020
13. Talmelli R., **Pallanti S.**, Bormolini G., Nardone G. Ossessioni e compulsioni. Le ritualità propiziatriche tra neuroscienze, demonologia e psicoterapia. Giunti Editori, 2021
14. Piga, R., **Pallanti, S.** Neurosport; Independently published 2022

Editor for an Italian Edition Book

1. BAARS-IV (Barkley Adult ADHD Rating Scale-IV), Russell A. Barkley, Hogrefe (2017), **Pallanti S.**, Salerno L.
2. The American Psychiatric Publishing Textbook of Psychiatry, Edited by R. E. Hales, S. C. Yudofsky, L. W. Roberts, Sixth Edition, Edra (2014). Manuale di Psichiatria, Editors: Sacchetti E., Mencacci C., Aguglia E., Albert U., Altamura C., Bogetto F., Clerici M., Colombo C., **Pallanti S.**, Santonastaso P., Smeraldi E., Zanalda E., Zuddas A.

### Digital Publications

2009 - 2013 CD-ROM for the the Managing Anxiety in Practice (MAP) educational programme

### Thesis

1. **Pallanti S.** (1983) Life events and Depression, Dissertation thesis for Medical
2. Doctorate Degree and European Medical License, University of Florence, School of Medicine, Florence, Italy.
3. **Pallanti S.** (1987) Life events and Schizophrenia, Dissertation thesis for PhD in Psychiatry, University of Florence, School of Medicine, Florence, Italy.
4. **Pallanti S.** (1992) Contingent Negative Variation (CNV) in normal elderly population, Dissertation thesis for PhD in Neurophysiopathology, University of Florence, School of Medicine, Florence, Italy.

### Other Publications

1. **Pallanti S.** Vincenzo Chiarugi, 1759-1820. American Journal of Psychiatry. 1996 Jul;153(7):944.
2. **Pallanti S.** Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. American Journal of Psychiatry 156:630-630, 1999.
3. **Pallanti S.** Obsessive-Compulsive Disorder: Theory, Research, and Treatment. American Journal of Psychiatry 1999; 156:1108a-1109
4. **Pallanti S.**, Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial. European Neuropsychopharmacology 10(S3), 127-128, 2000-09-30
5. **Pallanti S.** Pathological Gambling, A clinical guide to treatment, American Psychiatric Publishing, 2004, Introduction
6. **Pallanti S.** From impulse-control disorders toward behavioral addictions. CNS Spectrums. 2006;11(12):921-922.
7. **Pallanti S.** Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.

8. **Pallanti S.**, Book Review: Comprehensive care of schizophrenia: a textbook of clinical management, 2nd edition. American Journal of Psychiatry. 2013 Jan 1;170(1):125-126.
9. **Pallanti S.**, Strategies for Treatment Resistant OCD, Psychiatric Times. 2014.
10. **Pallanti. S.** L'Importanza dell'Ascolto del Paiziente: Dalla Psichiatria alle Neuroscienze Cliniche. Psicologia contemporanea (2022). 286: Dicembre-Maggio. Mente e Cervello. Isbn 9788809960343 pubblicato 23/11/2021. Giunti Editore

## EDITORIAL SERVICE

### Editorial Board Memberships

- Since 2000 Eating and Weight Disorders
- Since 2006 Journal of Gambling Studies
- Since 2010 Austin Child & Adolescent Psychiatry
- Since 2012 CNS Spectrums – International Journal of Neuropsychiatric Medicine
- Since 2012 Frontiers in Psychiatry
- Since 2012 Giornale Italiano di Psicopatologia
- Since 2014 British Association for Psychopharmacology Journal
- Since 2014 International Journal of Psychiatry in Clinical Practice
- Since 2016 Journal of Addiction and Therapy
- Since 2016 Journal of Psychiatry & Mental Disorders
- Since 2016 SM Journal of Psychiatry & Mental Health
- Since 2019 Real World Psychiatry and Psychopharmacology

### Editor/Editor in Chief

- 2000 & 2006 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Guest Editor
- 2008 - 2010 American Journal of Psychiatry Italian edition: Editor in Chief
- Since 2017 CNS Spectrums – International Journal of Neuropsychiatric Medicine: Field Editor
- 2019 Archive of Behavioral Addiction: Editor in chief
- 2022 Guest Editor, Special Issue Child Neuropsychiatry. Children (ISSN 2227-9067)

### International Advisor

- 2008 – 2012 American Psychiatric Publishing

### Reviewer

- Since 2000 American Journal of Psychiatry

Since 2000 JAMA of Psychiatry  
Since 2000 Journal of Psychiatric Research  
Since 2002 Biological Psychiatry  
Since 2004 Journal of Clinical Psychiatry  
Since 2006 European Neuropsychopharmacology  
Since 2010 Lancet  
Since 2010 Progress in Neuro-Psychopharmacology & Biological Psychiatry  
Since 2010 Psychiatry Research  
Since 2017 Frontiers in Psychiatry  
Since 2021 Annals of General Psychiatry

## GRANTS

2005 Italian Ministry of Health Research Fund, research on “Transcranial Magnetic Stimulation in Resistant Depression”, PI: Stefano Pallanti

2007 Italian Ministry of Education for University and Research PRIN Grant, research on Panic Disorder, PI: Stefano Pallanti

2009 Italian Ministry of Education for University and Research Grant for Collaboration agreement of Leland Stanford Junior University and University of Florence, PI: Stefano Pallanti

2010 Italian Ministry of Education for University and Research Prin Grant: “Repetitive Transcranial Magnetic Stimulation targeting inhibitory control networks in Anorexia Nervosa” PI: Stefano Pallanti

2017 – 2022 R21 Grant, The National Institute of Mental Health: “Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation”. MPI: Nikolas Makris; Co-PI: Stefano Pallanti Clinical Trial NCT03669315

2023 European Cooperation in Science & Technology (COST) CA16207 funding – European Network for Problematic Usage of the Internet (EU-PUI). PI for Italy: Stefano Pallanti

2024 – 2028 R01 Grant, The National Institute of Mental Health: “Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms and the effects on the brain”. MPI: Zora Kikinis; Role: Co-PI Stefano Pallanti. (under definition)

2023 – 2028 Horizon Grant, [European Health and Digital Executive Agency](#): “Boosting Societal Adaptation and Mental Health in a Rapidly Digitalizing, Post-Pandemic Europe”. MPI: Naomi Fineberg; Beneficiary for Italy Stefano Pallanti.

## RESEARCH PROECTS

- 2009 Ondansetron Augmentation in Treatment Resistant Obsessive-Compulsive Disorder, A single-blind, prospective study. Transcept Pharmaceuticals Inc. (CA), USA. Beneficiary for Italy: Stefano Pallanti
- 2009 Efficacy of Agomelatine, A randomised double-blind, placebo-controlled, parallel groups, international study. Servier International, France. PI: Stefano Pallanti
- 2010 International Multicenter Snapshot Study of OCD patients. International College of Clinical OCD (ICOCS). PI for Italy: Stefano Pallanti
- 2012 Phase II “A randomized, double-blind study comparing the efficacy and safety of tradozone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder” ANGELINI. PI: Stefano Pallanti
- 2012 Lurasidone: A 12-week multicenter open label study in subjects with Schizophrenia. LATUDA 2011 Phase III “Double blind placebo-controlled trial of Armodafinil in the treatment of Bipolar Depression” TEVA, Clinical Trial NCT01072929. PI: Stefano Pallanti
- 2012 – 2018 Phase IV “A non-interventional prospective cohort study of patients with persistent symptoms of schizophrenia to describe the course and burden of illness. Italian Society for Psychopathology 2012; Phase II “A phase 2, randomized, double-blind, placebo-controlled study to evaluate the effect pf add-on AMG 747 on schizophrenia negative symptom” AMGEN, Clinical Trial NCT01568229. PI: Stefano Pallanti
- 2016 ERA-NET NEURON European Community Transnational research projects - 'European Research Projects on External Insults to the Nervous System') “Role of repetitive Transcranial Magnetic Stimulation (rTMS) in Protease-Activated Receptor 1 (PAR1)-mediated alterations in synaptic plasticity for the treatment of traumatic brain injury sequels.” Plast4TBI, PI for Italy: Stefano Pallanti

## PRESENTATIONS

### International Meetings

- 2002 Course Director, Chairman, and Invited Speaker. European Certificate, International Master in Affective Neuroscience “Attentional Dysfunction in OCD Spectrum” Firenze, July 2002
- 2003 Course Director, Chairman and Invited Speaker. European Certificate, International Master in Affective Neuroscience “OCD and ADHD: a translational approach” Firenze, July 2003
- 2004 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Resistant OCD: Hoarding and attentional dysfunction”
- 2004 Organizer, Course Director, Chairman, and Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Anxiety and Impulsivity.” Firenze, 7 – 14 August 2004

- 2004 Course Director, Chairman, and Invited Speaker. European Certificate, International Master in Affective Neuroscience “OCD spectrum and comorbidities.” Firenze, July 2004
- 2004 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Neuromodulation for OCD: new targets”
- 2004 Poster Award European College of Neuropsychopharmacology (ECNP) “Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study”
- 2005 Stand Alone Lecture Tour in Japan on “New Vision of Pharmacological Intervention for the Acute Psychotic Patient” Tokyo, Yamanashi, Iwate, and Kobe. May 2005
- 2005 Invited speaker European College of Neuropsychopharmacology (ECNP) (Paris) “Treatment-resistant Obsessive-Compulsive Disorder: a translational vision.”
- 2005 Invited Speaker at World Psychiatric Association (WPA) “Improving remission in depression in Mediterranean countries.”
- 2005 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Treatment of difficult OCD”
- 2005 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Accelerating response to treatment of OCD”
- 2005 Organizer, Course Director, Chairman, and Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS. “Compulsivity-impulsivity and Pathological Gambling.” 30 July – 1 August 2005
- 2006 Invited Speaker European College of Neuropsychopharmacology (ECNP) (Amsterdam) “Gambling as compulsive disorder”
- 2006 Invited Speaker at World Psychiatric Association (WPA) “Anxiety Comorbidities and Role of Emotion in Endophenotype of Schizophrenia”
- 2006 Invited Speaker (Florida) American College of Neuropsychopharmacology “Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder”
- 2006 Lecturer, Solvay Pharmaceuticals Middle East Symposium (Beirut) “Social anxiety disorder: Assessment and treatment with SSRI “
- 2006 Invited Speaker International Anxiety Disorders Conference (Cape Town) “Resistant social anxiety disorder: how to get response.” February 2006.
- 2006 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Pharmacological challenge in OCD”
- 2006 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “OCD: Anxiety or addictive disorder?”
- 2006 Organizer, Course Director, Chairman, and Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Treatment of psychiatric disorder in the Day Hospital.” 14 – 15 September 2006.
- 2007 Invited Speaker at World Psychiatric Association (WPA) “Residual symptoms in depression.”

- 2007 Course Director, Chairman, and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Children with OCD: How to detect and treat”
- 2007 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Glutamate pathway in OCD”
- 2007 Organizer, Course Director, Chairman, and Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS. “Emotional endophenotype and schizophrenia”; “Resistant Depression: new treatment options” 31 August – 3 September, 2007.
- 2007 Invited Speaker, ECNP Targeted Expert Meetings (TEM). Speaker, “Behavioral and substance addictions: a new category.” Vienna, Austria
- 2007 Spokesman and Lecturer (Web Conference with Japan) Eli Lilly Web Conference Marketing in Japan “Treatment of Acute Psychosis and Schizophrenia.” June 2007
- 2008 Chairman of Symposium, ECNP TEM Meetings Participant, (Barcelona) “Dopamine and behavioral addictions”
- 2008 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “Endophenotype of impulsive-obsessive spectrum?”
- 2008 Chairman and Invited Speaker, International Forum on Mood, and Anxiety Disorders (IFMAD) (Vienna) “Is there an impulsive-obsessive spectrum?”
- 2008 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Social Anxiety in OCD disorders”
- 2008 Organizer, Course Director, Chairman, and Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “PANDAS: assessment and treatment”. Firenze, 4 – 6 September, 2008.
- 2008 Chairman and Speaker at Dinner Symposium on “Impulsive-Compulsive Spectrum Disorders: Diagnostic Issues”, American Psychiatric Association (APA) (Washington DC) “Pharmacological treatments of pathological gambling”
- 2008 Plenary Lecture World Psychiatric Association (WPA) “Adherence to treatment”
- 2009 Speaker at American Psychiatric Association (APA) “Unilateral low frequency versus sequential bilateral rTMS: is simpler better for treatment of resistant depression?”
- 2009 Lecturer Stand Alone Lecture Tour in Japan on “New Vision of Pharmacological Intervention for the Acute Psychotic Patient” (Tokyo, Aomori, Gumma, Tokushima, Fukuoka, and Kobe) “Acute schizophrenia”. October, 2009
- 2009 Course Director, Chairman and Invited Speaker (Florence) European Certificate, International Master in Affective Neuroscience “PANDAS and PANS”
- 2009 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Depression, OCD and neuroinflammation”
- 2009 Organizer, Course Director, Chairman and Invited Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS “Farmaci oltre lo studio STAR”; “Neuroimaging of Pathological Gambling”. Firenze, 5 – 7 2009



- 2009 Chairman and Invited Speaker, TEM Meetings participant, Plenary Lecture European College of Neuropsychopharmacology (ECNP) (Istanbul) "Pharmacological challenge in OCD and gambling disorder"
- 2009 Invited Speaker and co-chair of Symposium World Psychiatric Association (WPA). "Behavioral addictions, impulsivity and OCD". Firenze.
- 2009 Lecturer Solvay Pharmaceuticals Middle East Symposium. "Treatment of depression with selective serotonin inhibitors". Beirut, Lebanon, May 2009.
- 2009 Invited Speaker International Anxiety Disorders Conference (Amsterdam) "OCD : beyond Anxiety disorders"
- 2009 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich, and Paris) MAP – Managing Anxiety in Practice – Pfizer International "Management and treatment of GAD"
- 2009 Invited Speaker XV Update in Psychiatry. "Range of obsessive- compulsive disorders". Vienna, Austria.
- 2009 Invited Speaker International Anxiety Disorders Conference (Amsterdam) "OCD anxiety affective condition"
- 2010 Chairman and invited speaker, TEM Meetings participant, Plenary Lecture (Amsterdam) European College of Neuropsychopharmacology (ECNP) "Ondansetron augmentation in Treatment-Resistant OCD (TR-OCD): Relapse in Y-BOCS symptoms following discontinuation of ondansetron."
- 2010 Course Director, Chairman and Invited Speaker. European Certificate, International Master in Affective Neuroscience "Approaches to Treatment Resistance in OC Spectrum". Firenze, July 2010
- 2010 Chairman and Invited Speaker, International Forum on Mood, and Anxiety Disorders (IFMAD). "Augmentation strategies in resistant OCD". Vienna, Austria.
- 2010 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) MAP – Managing Anxiety in Practice – Pfizer International "Comorbid Anxiety in Bipolar Disorder and Psychotic Disorders: Impact on Outcome" "Managing Anxiety in Practice. Generalised Anxiety Disorder: The Hidden Companion",
- 2010 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) "PANDAS and PANS: is there an inflammation in OCD?"
- 2010 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS. "Trauma and Psychopathology in Daily Life", "Transcranial Magnetic Stimulation in Depression", "Evaluation and Treatment of Comorbidity for Anxiety in Psychosis", "Contributions of Transcranial Magnetic Stimulation to the Study of Awareness: Where Neuroscience meets Philosophy"
- 2010 Chairman of the TEM meetings and Invited speaker (Paris) European College of Neuropsychopharmacology (ECNP) "Ondansetron augmentation in Treatment-Resistant OCD: Twelve Week, Single-blind, Prospective Study Data"
- 2010 Lecturer Solvay Pharmaceuticals Middle East Symposium (Beirut (Lebanon), Amman (Jordan), Cairo, Alexandria, Ain Sokhna, (Egypt)) "Somatic depression and SSRI"

- 2010 Lecturer Solvay Pharmaceuticals Middle East Symposium (Zagreb) "SSRI and Sigma receptors"
- 2010 Invited Speaker Servier CL2-20098-072 Study Investigators Meeting (Amsterdam) "Efficacy of agomelatine in Obsessive-Compulsive Disorder."
- 2010 Invited Speaker Eli Lilly NERI European Consultant Advisory Board Meeting (Madrid) "Subjective Experience and Basic Symptoms in Schizophrenic Patients"
- 2011 Course Director and Invited Speaker (Berlin, London, Athens, Rome, Munich and Paris) MAP – Managing Anxiety in Practice – Pfizer International "Anxiety in women: special considerations" Neurotrophic Factors in GAD: A Closer Look at Brain-derived Neurotrophic Factor and Artemin
- 2011 Invited Speaker, Thematic Conference (Istanbul) World Psychiatric Association (WPA) "Gambling ADHD and mood stabilizers."
- 2011 Course Director, Chairman, and Invited Speaker European Certificate, International Master in Affective Neuroscience "Mood stabilizers in impulse control disorders". Firenze, July 2011.
- 2011 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) "Update on Agomelatin Preclinical and Clinical Data"
- 2011 Organizer, Course Director, Chairman, and Invited Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS "Recovery from OCD: a possible definition?"; "TMS in Depression and other clinical conditions". Firenze, 9 – 11 September, 2011.
- 2011 Chairman of the TEM meetings and Invited speaker (Paris) European College of Neuropsychopharmacology (ECNP) "Anxiety in the life span" "Disgust, passive-avoidance and treatment response in OCD"
- 2011 Invited Speaker (New York) Icare4Autism "Autism: Social Anxiety and executive dysfunction in adults."
- 2011 Invited Speaker (Milan) INNOPSY - International Forum Innovation in Psychiatry "Major Psychoses: Old concepts or new diagnostic clinical and therapeutic challenges."
- 2011 Invited Speaker (Florence) 3<sup>rd</sup> International Cardio Event – University of Florence "Emotional distress and cardiovascular diseases: Non-Pharmacological interventions."
- 2011 Invited Speaker (Thessaloniki) 2nd Panhellenic Inter-scientific Congress of the Hellenic Association for the Study of Internet Addiction Disorder "Internet Addiction Disorder."
- 2011 Invited Speaker European Congress of Psychiatry (EPA) (Vienna) "Generalized Anxiety Disorder", "Low frequency rTMS in elderly."
- 2012 Course Director and Invited Speaker London MAP – Managing Anxiety in Practice – Pfizer International "The GAD patient in focus.". London, UK.
- 2012 Chairman and Invited Speaker. Icare4Autism "Bio-Medical Research and Practice". Jerusalem, Israel.
- 2012 Course Director, Chairman and Invited Speaker. European Certificate, International Master in Affective Neuroscience "Treatment of anxiety in bipolar disorder". Firenze, July 2012.

- 2012 Member of the Board of Directors and Invited Speaker. International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) "Treatment of OCD in bipolar disorder".
- 2012 Organizer, Course Director, Chairman and Invited Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS "Application of rTMS in the OCD spectrum"; "PANDAS and PANDAS like in Psychiatry." Firenze, 19 – 21 October 2012.
- 2012 Chairman of the TEM meetings and Invited speaker; European College of Neuropsychopharmacology (ECNP) (Vienna) Chair, Brain Storming Session "Time for Immuno-Psychiatry?" Wien, Austria.
- 2012 Scientific Advisers Chair IFMAD International Forum on Mood and Anxiety Disorders "Development in the treatments of anxiety disorders", "Is Hoarding a separate disorder?" Barcellona, Spain.
- 2013 Course Director and Invited Speaker. MAP – Managing Anxiety in Practice – Pfizer International "Managing anxiety in practice: GAD now and beyond." Berlin, Germany.
- 2013 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting: "TMS in mixed bipolar episode". CA., USA.
- 2013 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting "The Emotional Endophenotype in Schizophrenia"
- 2013 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy "Pathological gambling: new diagnostic boundaries and treatment options."
- 2013 Chairman of the TEM meetings and Invited speaker European College of Neuropsychopharmacology (ECNP)(Barcellona) "The role of anxiety in impulsive and compulsive disorders"
- 2013 Course Director, Chairman, and Invited Speaker European Certificate, International Master in Affective Neuroscience "ADHD in bipolar disorder: Assessment and treatment". Firenze, July 2013.
- 2013 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) "TMS for OCD: where are the targets?"
- 2013 Organizer, Course Director, Chairman, and Invited Speaker. Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS "Adult ADHD and Bipolar Disorder". Firenze, 11 – 12 October 2013.
- 2013 Speaker, Stanford University, Florence, Italy. "The Trapped Brain (Gambling, Internet addiction and other pathologies: how to recognize and prevent them"
- 2013 Invited Speaker. International Society of Addiction Medicine (ISAM) Conference "Internet Addiction: NO Substance Addiction?" Kuala Lumpur, Malaysia.
- 2013 Chairman, Co-Chairman, Invited Speaker (Milano) World Congress on ADHD Chair: "How to do best medication in adult ADHD?"; Co-Chair: "Update on treatment of ADHD across the lifespan."
- 2014 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting "rTMS as an add-on therapeutic tool in treatment refractory obsessive-compulsive disorder"

- 2014 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting “Low frequency bilateral rTMS in resistant OCD subjects: does the effect last?”
- 2014 Invited Speaker (Madrid) World Psychiatric Association (WPA) “Repetitive behavior disorders as a target for focal treatment.”
- 2014 Chairman and Invited Speaker (Online meeting Eli Lilly) ADHD in Adult: Raise the Awareness of a Disease Still Unknown and Not Recognized “TMS for ASD and OCD”
- 2014 Chairman of the TEM meetings and Invited speaker European College of Neuropsychopharmacology (ECNP) (Berlin) "Adult separation anxiety disorder: boundaries causes and potential treatments"; “Is a paradigm shift in Psychiatry long overdue?”
- 2014 Course Director, Chairman and Invited Speaker. European Certificate, International Master in Affective Neuroscience “Obsession and compulsion: an R-DoC approach” Firenze, July 2014.
- 2014 Chairman and Invited Speaker, International Forum on Mood, and Anxiety Disorders (IFMAD) (Vienna) “Pharmacologic treatment of Obsessive-compulsive comorbidity”; “How to treat anxiety with comorbidity.”
- 2014 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Neuromodulation: deep TMS and rTMS”
- 2014 Organizer, Course Director, Chairman and Invited Speaker (Florence) Florence Summer Course – University of Florence and Clinical Neurosciences ONLUS. Speaker, “Cure Comorbidities.” and “Neuromodulation for resistant disorders.”
- 2015 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy “Pluses and minuses of DSM-5 in depression and anxiety disorders”; “Neurobiology of addictive behaviors.”
- 2015 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting “The clinician as a translational scientist “
- 2015 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting “OCD with theta burst stimulation (TBS) of the pre-supplementary motor area (pre-SMA).”
- 2015 Scientific Advisory Board and Chairman of the TEM meeting and Invited speaker European College of Neuropsychopharmacology (ECNP) (Amsterdam) “Separation anxiety in adults”
- 2015 Invited Speaker (Milan) EXPO 2015 Symposium “Il Futuro della Salute Mentale” (Future of the Mental Health) “The Obsessive-Compulsive Patient.”
- 2015 Course Director, Chairman, and Invited Speaker. European Certificate, International Master in Affective Neuroscience “Separation anxiety in ADHD”. Firenze, July 2015.
- 2015 Chairman and Invited Speaker, International Forum on Mood, and Anxiety Disorders (IFMAD) (Prague) “Pluses and minuses of DSM-5 in depression and anxiety disorders”
- 2015 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Multicenter rTMS trial”

- 2016 Invited Speaker (Brescia) Brixia International Meeting – University of Brescia, Italy “Neuromodulation of compulsive disorder: Experience and perspectives”; “Behavioral addiction: decision making and executive function disorder.”
- 2016 Member of the Editorial Board and Invited Speaker CNS Spectrum Meeting “Executive functions and OCD”
- 2016 Member of the Board of Directors and Invited Speaker Clinical TMS Society Meeting “TMS for autism spectrum disorders”
- 2016 Scientific Advisory Board, Chairman of the ECNP Targeted Expert Meetings (TEM) meeting and Invited speaker European College of Neuropsychopharmacology (ECNP)(Vienna) “Future perspectives for treatment of anxiety disorders”
- 2016 Chair of Symposium on “New neural treatment targets in compulsive disorders”. American Psychiatric Association (APA) “Repetitive behavior disorders as a target for focal treatment: TMS for ASD and OCD”. Atlanta, USA.
- 2016 Expert in Psychiatry, Chair, and Invited Speaker 4<sup>th</sup> ACNS – Asian Clinical Neurosciences Summit Speaker “What is an integrated approach, and how does it help patients to achieve functional recovery? Expert Session: “Treatment of bipolar disorder patient with comorbid metabolic disorder”; Speaker “Targeting neuroinflammation in psychiatry: a prelude to optimal treatment?”; Speaker: “Reframing women’s mental health: what are we missing?” Bangkok, Thailand, 23 – 24 April 2016.
- 2016 Course Director, Chairman and Invited Speaker. European Certificate, International Master in Affective Neuroscience “Fear, Obsession and Trauma”. Firenze, July 2016.
- 2016 Chairman and Invited Speaker, International Forum on Mood and Anxiety Disorders (IFMAD) (Rome) “How should we treat resistant OCD?”
- 2016 Member of the Board of Directors and Invited Speaker International College of Obsessive-Compulsive Spectrum Disorders Meeting (ICOCS) “Pre-SMA target for TMS in OCD”
- 2016 Stand Alone Web Cast Lecturer (Online World-wide) Pfizer CNS World-wide Web Cast Series “Neuro-inflammation and Mental Disorders.”
- 2016 Executive Committee Meeting (Madrid) European College of Neuropharmacology (ECNP) “Future perspectives for the treatment of anxiety disorders”
- 2017 SOPSI Italian Society of Psychopathology annual meeting, Speaker, “Neuromodulation therapy for Major Depression.”
- 2017 Weekend Educational Course in India. Speaker, “OCD – The State of the Art”. New Delhi, India. 26 – 28 May 2017.
- 2017 Executive Committee Meeting (Nice) European College of Neuropharmacology (ECNP). Paris, 2 – 5 September 2017.
- 2017 25th European Congress of Psychiatry (EPA).  
Speaker “anxiety disorders and somatoform disorders: depression, obsessive-compulsive disorder and personality disorders”  
Symposium “Impulsivity, Compulsivity and Behavioral Addiction”  
Symposium “New neural treatment targets in compulsive disorders”  
E-Poster Walk. Firenze, 2 – 4 April, 2017.

- 2017 18<sup>th</sup> World Congress Creative Processes in Psychotherapy and Psychiatry. Speaker “Unconscious and Neurosciences”. Speaker “The impact of imaging brain circuitries in neuroscience and neuropsychanalysis”. 20 April 2017.
- 2018 Conference Pharmacological treatments in the therapeutic-rehabilitative process of the substance user. Speaker "The neurobiological roots of non-pharmacological treatments in the integrated field."
- 2018 International Conference on Transcranial Magnetic Stimulation and addiction treatments, Torino, Italy, 20 April 2018. Speaker “Neuromodulation of impulsivity and compulsivity: targeting inhibitory control networks across impulsive-compulsive disorders?”
- 2018 Weekend seminar in India. Speaker and Discussant, “Treating Resistant OCD”. Bangalore, India. 25 – 27 May 2018.
- 2018 European College of Neuropharmacology (ECNP), Barcelona, Spain, 6 – 9 October 2018.  
Chair “Transcranial Magnetic Stimulation (TMS): From benchmark to bedside”  
Speaker “Highlights in OCD and related disorders”  
Executive Committee Meeting
- 2018 Italian Society of Psychiatry Meeting, Torino, Italy, 16 October 2018.  
Presentation: Cariprazine: Clinical usefulness and therapeutic experience in the real world
- 2018 Executive Committee Meeting (Toledo) European College of Neuropharmacology (ECNP), 16 – 18 December 2018
- 2019 XXIII SOPSI Società Italiana di Psicopatologia annual meeting, Speaker, Cariprazine and personalized care, ADHD throughout life, ADHD: Neurological signs and subjective experience, 20 – 23 February 2019
- 2019 Sage Therapeutics, Inc. European Advisory Board “the potential role of the GABA pathway in the future management of depressive episodes” 5 April 2019
- 2019 Octapharma PANS Advisory Board Meeting, Phoenix 27 April 2019
- 2019 Milano Psichiatria, Speaker, 1. Evolution of pharmacotherapy in schizophrenic spectrum disorders: from control to treatment, 2. Behavioral Addictions: Beyond Gambling, 3. Personalized TMS for depression. Discussant: Where a gambling policy can go that leaves internet gaming and illegal gambling at the margins? 13 – 16 May, 2019
- 2019 Società Italiana di Psichiatria, Speaker, Cariprazine: "Making Sense" Therapeutic Value of a new Care Tool, Torino, 21 May 2019
- 2019 IFMAD International Forum on Mood and Anxiety Disorders, Speaker, Personalized rTMS in Depression, 4 - 6 July 2019, Wien, Austria.
- 2019 Harvard University and the Massachusetts General Hospital Psychiatry Academy, Faculty, Session 1. Bipolar Depression and Mixed Features” Session 2. “Updates on TMS in Depression”. Stresa, 12 - 14 July 2019.
- 2019 32<sup>nd</sup> ECNP Congress, Copenhagen, Task Force network Meeting, Industry Network Meeting, TWG meeting, 1st EC Meeting, Satellite Symposia – Speaker “Patient functioning in schizophrenia: can we change the burden?” 7 – 10 September 2019
- 2019 Comprehensive Psychiatry Editorial Board Meeting Elsevier, Copenhagen 10 September 2019

- 2019 12th Congress of the Italian Society of Biological Psychiatry, Naples, 2 – 4 October 2019 Speaker "Use of TMS in Psychiatric Disorders"
- 2019 Conference Emotions, knowing them, inducing them to manage them: Speaker "Disgust, contempt and other figures of lack of love" Florence, 9 November 2019
- 2019 Albert Einstein College of Medicine lecture "TMS in the impulsive-compulsive spectrum" New York, 17 December 2019
- 2020 ECNP Task Force Meeting, Leiden, Netherlands. 10 February 2020
- 2020 Società Italiana di Psicopatologia, Speaker "The evolution of pharmacotherapy in schizophrenia: Cariprazine and the Why for a change. Roma, 20 February 2020
- 2020 European Commission consensus initiative on depression and its treatment London, UK. 22 May 2020
- 2020 First Master Training Class in Neuromodulation, Organizer and Speaker, "Clinical findings of TMS in OCD spectrum", Online event, 5-6 June 2020
- 2020 Advisory Board on Trazodone, Speaker, Online event, 23 July, 4 August 2020
- 2020 VI Conference of Epigenetics, Urbino. Speaker "The brain suffers: from life to the clinic" Milan, 3-4 October 2020.
- 2020 Institute of Natural Medicine 2020 Microbiota course: pathophysiological, clinical and therapeutic aspects, Speaker, 30 October 2020. University of Florence.
- 2020 SCOPUS International Webinar. Speaker, COVID pandemic and its impact on Mental Health. 27 August 2020, New Delhi, India
- 2020 2nd Forum of Advanced Training in Psychiatry. Speaker, Prevention, early interventions and new treatment opportunities in schizophrenia and mood disorders. Brescia, 3-4 December 2020.
- 2021 XXII Congresso Nazionale SINPF, Società Italiana di NeuroPsicoFarmacologia. Speaker, Schizophrenic spectrum disorders; from control to recovery through care: experiences with cariprazine. 28 January 2021.
- 2021 Web Forum Cognitive and depressive disorders of the elderly. Speakers, current situation and therapeutic innovations. Milan, 2 February 2021. Academy of Natural Therapy
- 2021 Symposium Psychotropic drug schizophrenic spectrum therapy. Speaker, From objective and functional clinical recovery to personal recovery. Milan, 28 February 2021. Academy of Natural Therapies.
- 2021 The new trends in the treatment of mental disorders. Speaker, Where is ADHD hiding among adults? 18 February 2021. La Sapienza University
- 2021 Online Webinar, Order of Psychologists of the Tuscany Region. Speaker, "Technology at the service of the clinic." 25 February 2021.
- 2021 The Brain Somewhere else: Behavioral Addiction in the age of Internet. Speaker, Neuromodulation in Behavioral Addictions. 9 April 2021. La Sapienza University.
- 2021 3rd International Psychopharmacology online course, Harvard University and Massachusetts General Hospital Psychiatry Academy. Depression & Schizophrenia. International Perspectives on Global Disorders. Speaker, Bipolar Depression: How do we treat it? 14 May 2021.

- 2021 Summer School on Affective Neuroscience. Speaker, TMS for OCD spectrum: toward personalization. 30 June 2021. International master's degree in Affective Neuroscience, University of Maastricht and University of Florence.
- 2021 19<sup>th</sup> International Forum on Mood and Anxiety Disorders. Speaker, Adult ADHD diagnosis, comorbidities, and treatment. Budapest, Hungary. 22 – 24 July 2021.
- 2021 International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), Lisbon. Speaker, Immune-inflammatory mechanisms, and therapeutics in OCD in the post Covid era. 1 October 2021.
- 2021 Theoretical and practical Transcranial Magnetic Stimulation Course in Psychiatry. Speaker, Use of Transcranial Magnetic Stimulation in OCD and other Obsessive-Compulsive Spectrum Disorders. Rome, 21 October 2021
- 2021 Continuing Medical Education seminar, Depression Focus 2021, Online event. Speaker, Non-pharmacological Therapies. 4 November 2021.
- 2021 International Web Forum "Psychiatric and neurological issues in the Covid-19 era". Speaker, Covid-19 outbreak and major neuropsychiatric disorders: the inflammatory bridge. 11 November and 21 January 2022. Menarini group.
- 2021 XIII Course Institute of Psychopathology "New evidence from the real world in psychiatry and psychotherapy". Speaker, Role of TMS in the treatment of OCD spectrum disorders. 13 November 2021
- 2022 International Web Forum "Psychiatric and neurological issues in the Covid-19 era". Speaker "Digital psychiatry during the Covid-19 pandemic: a promising help for patients, families, and health care professionals". Webinar, 20 January 2022
- 2022 Jornada Científica Internacional: Avances en Neurociencia. Universidad de Las Palmas de Gran Canaria, Salud Mental y Educación (Mental Health and Education): Introduction of Dr. Lluís Serra, Magnífico Rettore ULPGC. Presentation title: Mental Health Today: Psychiatry and Society - La Salud Mental Hoy: Psiquiátrica y Sociedad. Speaker, Non-Invasive Neuromodulation in Clinical Neuroscience Las Palmas de Gran Canaria, Spain. 22 February 2022.
- 2022 Stand Alone Presentation: Personalized rTMS for Treatment Resistant Disorders. Instituto Universitario de Neurociencia, Universidad de la Laguna, Spain. 21 February 2022
- 2022 National Conference of the Academy of Natural Therapies. Speaker, Use of phytotherapeutics, probiotics and nutraceuticals in the OCD spectrum: augmentation and monotherapy. 17 – 18 March 2022.
- 2022 Curso de TDAH Infantil – Adolescente – Adulto (Child-Adolescent-Adult ADHD Course). Speaker, Comprehensive ADHD approach in CSM and specialized programs. Psychopharmacological, cognitive-behavioral, psychoeducational treatment. Presentation Title: Research and its clinical application of the neuromodulation treatments. Madrid, Spain. 16 – 17 March, 2022. Hospital Universitario del Sureste.
- 2022 Società Italiana di Microbiologia webinar: Physiopathological, Clinical and therapeutic Aspects. Speaker, Microbiota and Depression. 18 March, 2022.
- 2022 Conference The integrated clinical approach and rTMS in neurological and psychiatric fields. Speaker, rTMS and pharmacological approach in the spectrum of obsessive-compulsive disorders. Rimini, 2 April 2022.
- 2022 Conference sponsored by the Marche Region, Asur Area Vasta 4 and sociale XX.



- Speaker, Mental Health: "You try to have a world in your heart AND you can't express it with words." Sant'Egidio a Mare, Rome, Civitanova 19 March 2022.
- 2022 Conference Company Social Health Unit Veneto. The inflammatory state in Neurology: enemy agent and therapeutic ally. Speaker, How and why to evaluate and treat inflammation in the Obsessive Spectrum. compulsive, inattentive and depression Vicenza, 22 April 2022
- 2022 Royal Society of Medicine Educational Programme PYQ58 - Mind Matters. Speaker. London, 28 April 2022
- 2022 Psicologia.io online presentation "Psychology and Behavioral Health". 23 May 2022
- 2022 Summer School on Affective Neuroscience. Speaker, TMS for OCD spectrum: toward personalization. International Master's Degree in Affective Neuroscience, University of Maastricht and University of Florence. Leuven, Belgium. 6 July 2022.
- 2022 Autism Spectrum and Neurodevelopmental Disorders. Speaker, "Neuromodulation for autism spectrum disorders: photobiomodulation". Ancona, 20 September 2022.
- 2022 Non-invasive brain stimulation in Psychiatry: the case of TMS. Scientific Director. Speaker, "Treatment resistant OCD: pharmacological and TMS approach", "Cognitive and negative symptoms in Schizophrenia: what's new?" Roma, 22 23 September 2022
- 2022 Obsessive-Compulsive Disorder after DMS 5. Speaker. La Sapienza, Roma 30 September 2022.
- 2022 Ischia International Architecture Award. Speaker, Neuroscience and architecture. Ischia, 7 October 2022
- 2022 Chairman of the Neuromodulation Network meeting, European College of Neuropsychopharmacology (ECNP) Wien, Austria, 16 November 2022
- 2023 Academy of Natural Therapy in Psychiatry and Neurology. Natural Medicine in Psychiatry and Neurology: evidence 2023. Speaker "Use of phytotherapeutics, probiotics and nutraceuticals in Anxiety Disorders and in the Obsessive Spectrum: augmentation and monotherapy" Speaker, "Natural treatments of inflammation for Psychiatric Disorders after Covid19" Milano Fondazione Stelline, 12 – 13 January, 2023.
- 2023 Università della Laguna Tenerife. 1st International Winter Course and Workshop on Neuroimaging: Brain Connectivity and Mental Health. Scientific Director. Clinica e Fenomenologia: Speaker, "OCD". TMS and Neurosciences: Speaker, "TMS Clinica in OCD Spectrum" Tenerife, Spain. 7 – 8 February 2023.
- 2023 Harvard University and Massachusetts General Hospital Psychiatry Academy annual course. Photo-Bio-Modulation, Clinical experience with PBM treatment: Speaker, "A case series of children with ASD and a single case of gene SCN2A-related autism in a young adult". Online event, 17 March 2023.
- 2023 My Brain Matters <https://www.my-brain-matters.com>. Brain + Transcranial Photo-modulation Therapy Virtual Summit. Speaker, **Photobiomodulation in Autism Spectrum Disorder: Clinical Experience. Since March 2023**
- 2023 Stand Alone Lecture. Behavioral Addictions such as Brain Connectivity Disorders and Transcranial Magnetic Stimulation. the Order of Physicians and Dentists of the Province of Monza. Monza, 5 May 2023.

- 2023 Conference: The Integration of Mind-Body and Mental Health: A Budo Perspective. Speaker, "Quantum Movement: Energy applied to movement." Firenze, 19 May 2023.
- 2023 Conference: Human Connectome, RDoC and TMS. Speaker, "From myths to neuroscience: obsessions as connectivity disorders: therapeutic target and treatment with rTMS". Universidad de la Laguna, Spain. 9 June 2023
- 2023 Università degli Studi Firenze and Maastricht University Summer School on Affective Neuroscience at the crossroads of science and clinical practice. Summer Course on Mood, Aggression and Attraction. Speaker, "TMS for Behavioral Addiction". Irish College Leuven, Belgium. 2 – 7 July 2023
- 2023 4th International Congress of the World Association for Stress Related and Anxiety Disorders (WASAD). Dealing with stress and anxiety in a world of chronic crisis: What we can learn from translational perspectives. Chair, Plenary Session ADHD and Stress under different perspectives. Speaker, Emotional dysregulation in ADHD, and treatment outcome. A summary of the evidence. Stand Alone conference: PANDAS a polarized discussion: Update of evidence and experience in the post\_Covid Age. Eidgenössische Technische Hochschule Zürich (ETH Zurich), ETZ, Zurich, Switzerland, 11 – 13 September 2023
- 2023 36<sup>th</sup> annual Congress of the European College of Neuropsychopharmacology ECNP. Stand Alone presentation at the Neuromodulation Network and Thematic Working Group. Barcelona, 7 – 10 October 2023
- 2023 Simposio sul Cambiamento. Speaker, "Le dipendenze comportamentali: come cambiare comportamento". Speaker, Peccioli, 14 October 2023
- 2023 Pain Medicine: the Challenge. Aggiornamenti in Medicina del Dolore. Speaker, "Fibromialgia: specialisti a confronto". 26-28 October 2023, Rimini
- 2023 Società Ticinese di Psichiatria e Psicoterapia (STPP) Formazione continua. Speaker, "Diagnosi di precisione per la cura personalizzata: la Psichiatria basata sulle Neuroscienze". Online event, 26 October 2023
- 2023 I Disturbi Affettivi di Genere nell'Era dell'Imprevedibilità. Speaker, "Disturbi della Personalità" Firenze, 10 November 2023
- 2023 Università di Catania European Frontiers in Neuroscience seminar series. Grand Rounds, "Behavioral Addictions: Prevention and Treatment". Catania, 22 November, 2024
- 2023 3° Forum Nazionale SIPG "Psichiatria Geriatrica 2023. Coordinator and Moderator, 20 Minisimposio monotematico Il continuum farmaci - trattamenti naturali per l'anziano con deficit cognitivi. Stand alone lecture: Il continuum terapeutico farmaci – trattamenti naturali per l'anziano con problem dello spettro ossessivo. Milano, 23 – 24 November 2023
- 2024 Cambridge University Gambling Research Consortium Meeting. Grand Rounds, "TMS in gambling disorder" Camgrige, 23 January 2024

- 2024 Universidad della Laguna Tenerife. 2nd International Winter Course and Workshop on Neuroimaging: Theoretical Course on Neuroanatomy, Basic & Clinical Neuromodulation and Neuroimaging. Speaker, "TMS in Gambling Disorder and Behavioral Addiction". Santa Cruise de Tenerife, 1 - 4 February, 2024.
- 2024 ECNP 3<sup>rd</sup> Masterclass on Neuromodulation: Precision TMS. Organizer, coordinator and speaker, "Clinical findings of TMS in OCD spectrum". Online event, 16 – 18 February 2024.
- 2024 III International Conference on Bioethics, The Metamorphosis of the Body: Bioethics and Neuroscience. Speaker, "Neuroscienze post-Covid e l'inconscio non mentale". University of Malta, 7 – 9 March 2024.
- 2024 Schweizerische Fachgesellschaft ADHS (Swiss Association for ADHD) Meeting. ADHD in Old Age. Speaker, "Aging with ADHD". Zurich, 14 – 15 February 2024.
- 2024 35th World Congress Collegium Internationale Neuro-Psychopharmacologicum CINP Neuromodulation webinar. Speaker, TMS basic principles, clinical uses, and research principle: toward precision TMS. Tokyo, 23 – 26 March 202.

### GRAND ROUNDS

- 2012 University of Sydney, Brain and Mind Institute, Sydney, Australia "Social Anxiety in Autism Spectrum Disorders: a new target for new treatments?"
- 2013 Albert Einstein College of Medicine of Yeshiva University, New York, USA "Psychoses and Anxiety"
- 2016 Center for Neuropsychopharmacology, Centre for Restorative Neuroscience, Division of Brain Sciences, Faculty of Medicine, Imperial College, London, UK "Investigating and Treating Compulsivity with neuromodulation"
- 2023 Università di Catania European Frontiers in Neuroscience seminar series. Grand Rounds, "Behavioral Addictions: Prevention and Treatment". Catania, 22 November, 2024
- 2024 Cambridge University Gambling Research Consortium Meeting. Grand Rounds, "TMS in gambling disorder" Camgrige, 23 January 2024

### DEVELOPMENT OF AN ASSESSMENT TOOL

Pathological gambling PG-YBOCS (Pathological Gambling Yale-Brown Obsessive-Compulsive Scale).

### PAID CONSULTANCY AGREEMENTS

- |      |                                    |
|------|------------------------------------|
| 2000 | Otsuka Pharmaceutical              |
|      | Solvay International (Fluvoxamine) |
| 2001 | Solvay International (Fluvoxamine) |
|      | Otsuka Pharmaceutical              |

2002	Pfizer (Pregabalin SR) Pfizer (Pregabalin SR) Otsuka Pharmaceutical
2003	Pfizer (Pregabalin SR) Otsuka Pharmaceutical
2004	Pfizer (Pregabalin SR) Otsuka Pharmaceutical
2005	Ely Lilly Otsuka Pharmaceutical
2006	Pfizer (Pregabalin SR) Transcept Pharmaceutical (Ondansetron) Otsuka Pharmaceutical
2007	Pfizer (Pregabalin SR) Ely Lilly Pfizer (Pregabalin SR) Otsuka Pharmaceutical GSK (Bupropion SR) Jazz Pharmaceutical (Fluvoxamine) Transcept Pharmaceutical (Ondansetron)
2007 - 2010	An International Tobacco Company (Nicotin Dipendence Litigation)
2008	GSK (Bupropion SR) Jazz Pharmaceutical (Fluvoxamine) Pfizer (Pregabalin SR) Otsuka Pharmaceutical Transcept Pharmaceutical (Ondansetron) Brainsway (Neuromodulation technology)
2009	Astrazeneca Intramed Ely Lilly Innova Pharma Pfizer (Pregabalin SR) Otsuka Pharmaceutical Transcept Pharmaceutical (Ondansetron)
2010	Intramed Mind Education and Reserch in Neuroscience and Medicine Abbot Laboratories Egypt Ely Lilly Solvay Group Lundbeck Pfizer (Pregabalin SR) Otsuka Pharmaceutical Transcept Pharmaceutical (Ondansetron)
2011	Grunenthal GmbH Servier Group Innova Pharma Lundbeck Pfizer (Pregabalin SR) Otsuka Pharmaceutical Transcept Pharmaceutical (Ondansetron)
2012	Chadbourne &Parke LLP, London, UK Innova Pharma Alkermes Pharmaceuticals

Lundbeck  
 ALKS-5461 MDD Advisory Board, Alkermes Plc  
 ProPhase, LLC  
 Angelini  
 Servier Group  
 Biotest AG  
 Sunovion Pharmaceuticals  
 Pfizer (Pregabalin SR)  
 Otsuka Pharmaceutical  
 Transcept Pharmaceutical (Ondansetron)

2013

Chiltern International  
 Innova Pharma  
 Agence Nationale de la Recherche, ANR France  
 Pfizer Limited  
 Stanford University, Florence, Italy  
 Innova Pharma  
 Spectrum Neuroscience and Treatment Institute  
 Transcept Pharmaceutical (Ondansetron)

2014

Ely Lilly  
 Innova Pharma  
 Agence Nationale de la Recherche, ANR France

2015

Ely Lilly  
 Innova Pharma

2016

L.E.K. Consulting  
 Innova Pharma  
 Recordati

2017

Recordati  
 Innova Pharma

2018

Sage Therapeutics Inc  
 Recordati  
 Swiss National Science Foundation (SNSF)  
 Innova Pharma

2019

Octapharma  
 Neurocrine Biosciences  
 Recordati  
 Sage Therapeutics  
 L.E.K. Consulting  
 Swiss National Science Foundation (SNSF)  
 Pfizer  
 Centro di Terapia Strategica srl  
 Innova Pharma

2020

Recordati  
 The Forensic Panel  
 L.E.K. Consulting  
 Biohaven Pharmaceuticals, inc  
 EMBS Group spółka z ograniczoną odpowiedzialnością spółka komandytowa  
 Angelini Pharma  
 GEDEON RICHTER Plc  
 Association of Analytical Child and Adolescent Psychotherapists in Germany  
 (Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in  
 Deutschland e. V., VAKJP)  
 Swiss National Science Foundation (SNSF)

2021	Innova Pharma Recordati Biohaven Pharmaceuticals, inc Angelini Pharma GW Research Limited Innova Pharma Swiss National Science Foundation (SNSF) for Spark funding instrument Lundbeck Otsuka Pharmaceutical Aboca Biogen Menarini
2022	Neopharmed Gentili Lundbeck Biohaven Pharmaceuticals, Inc Beckley Psytech Medpace Acsel Health Biogen
2023	Neopharmed Gentili Biohaven Pharmaceuticals, Inc Biogen

LITIGATION HISTORY: Won all cases reviewed and worked

Plaintiff work

2013: Military Jurisdiction: Compagnia Carabinieri (Italian Armed Military Police Force) against a criminal previously sentenced not guilty

2018: Damage against an Insurance company

Defense Trials

2006-2007: Class action performed by a cohort of workers who claimed to be victims against Boeringer UK

2012-2013: Noise pollution action performed by a cohort of people who claimed to be victims against Phillip Morris / Smurfit Kappa

2012 A lottery betting shop owner (a pathological gambler) sued by Italian Ministry of Treasury

2016: A medical doctor sued by his patient for sexual harassment

2011-2020: 9 cases (family, work and accidents)

COMMUNITY SERVICE

2000	Technical and Scientific Medical Consultant for the Italian Ministry of University and Scientific Research and Technology
2000 - Present	“Forteto” Litigation case Consultant
2000 – Present	Servants of the Holy Paraclete Consultant
2012 - Present	Technical Consultant for the Avvocatura dello Stato (Italian Republic State Advocacy)
2013 - Present	Technical and Medical Conosultant for the Compagnia Carabinieri (Italian Armed Military Police Force)